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General Introduction. 
 
Over the last fifteen years, reoperative coronary artery bypass grafting (RECABG) has 
become one of the major areas of interest in the department of Thoracic and Cardiac Surgery 
of the University Medical Center Nijmegen, St. Radboud, The Netherlands. Not only was 
there increasing surgical experience, but also several papers concerning RECABG were 
published in national and international journals. In 1996 several of these papers were 
summarized in a book called  “Coronaire Heroperaties. Een evaluatie”*.  
 The publications of results can be seen as a kind of quality control of the surgery 
performed and can spur the authors to update their knowledge and confront the new problems 
and questions of RECABG. Such surgery can be described as disastrous, adventurous, 
frustrating, trying and presents many cha llenges to the surgical team. Two essential points 
must, however, be remembered. Firstly, RECABG is the consequence of primary coronary 
artery bypass surgery (CABG) and secondly, whereas modern cardiac surgery has become 
relatively safe, RECABG continues to have a high morbidity and mortality compared to 
CABG. 
 
This thesis consists of several articles related to two major points:  
· The influence of the evolution in CABG on RECABG. 
· Analysis of the early postoperative mortality. 
   
Chapter I gives a general review of problems of RECABG.  In Chapter II the changing profile 
of patients undergoing RECABG is presented. In chapter III the short and long term results, 
of RECABG in patients, with a patent internal mammary artery are discussed. The chapters 
IV to VI deal with the problem of early (six months) mortality. Chapter IV analyses 
determinants associated with early mortality following RECABG. In Chapter V and VI the 
results of the study presented in chapter IV are used to construct a preoperative (Chapter V) 
and a postoperative (Chapter VI) predictive model of early mortality in RECABG. Chapter 
VII presents the results of the long-term survival after RECABG, and confirms again the 
importance of the first six months for the long-term survival. Our preliminary results on 
quality of life after RECABG are presented in Chapter VIII. Summaries and general 
conclusions in English and Dutch are presented in Chapter IX   
 
* Coronaire Heroperaties. Een Evaluatie. Noyez L. (eds). ISBN 90-803014-1-8, NUGI 742, Universiteits 
drukkerij Nijmegen, 1996 
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Incidence. 
 
 In 1983, Loop postulated that about 7% of patients undergoing primary coronary arterial 
bypass grafting (CABG) in time would need a second operation for recurrent angina [1]. During 
the last decade, much has changed in the fields of cardiac surgery, anesthesia and intensive care, 
which have resulted in lower mortality rates and a shift away from cardiac related mortality and 
morbidity after CABG to non-cardiac related mortality and morbidity [2-4]. Loop’s postulation, 
however, has turned out to be true because the percentage of reoperative coronary artery bypass 
grafting (RECABG) currently varies between 6-10% of the patient population. [1,5,6] There 
seems to be a paradox here. On the one hand the results of CABG have improved remarkably 
with longer life expectation of the overall population even with the acceptance of older patients 
for cardiac surgery. On the other hand, more patients with suboptimal distal coronary arteries 
undergo CABG with a higher risk of recurrent angina. (table 1)  
 
Table 1 Factors which may increase or decrease the rate of RECABG 
Increase Decrease 
Use of saphenous vein grafts only Use of arterial grafts 
Failure of operative technique Complete revascularization 
Progression of atherosclerosis Antiplatelet drugs  
Incomplete revascularization Statines 
Younger age at the primairy operation Balloon Angioplasty - Stenting 
Older age at the reoperation  
Hyperlipidemia   
Diffuse coronary pathology  
    
Early and late return of angina - early and late graft failure 
 
Coronary artery bypass surgery is a well-recognized treatment for coronary artery 
disease. The use of arterial grafts have improved long-term results in terms of survival as well as 
in return of ischemic symptoms. [7-10]  However, the process of atherosclerosis cannot be 
stopped and the return of angina pectoris seems inevitable.  This return seems to be biphasic: an 
early return of angina pectoris within six months after CABG, and a late return more than six 
months after CABG. Early graft failure, due to intimal fibroplasia, [11] and incomplete 
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revascularization are the main reasons for the early return. Late return is due to progression of 
atherosclerosis in the native coronary artery system, in the vein grafts, or both (table 2).  
 
Table 2 Return of angina post myocardial revascularization 
Return of angina                       Cause  
Early (< 6 months) - Surgical-related problem 
- Incomplete revascularization 
- Intima fibroplasia  
 
Late (> 6 months) - Progression of atherosclerosis in the native coronary system (PA) 
- Atherosclerosis in grafts (AG) 
- Combination of  PA + AG 
- Incomplete revascularization 
 
It seems that the reason for RECABG is time related: in the early seventies, the majority of the 
patients underwent a RECABG because of progression of atherosclerosis in the native coronary 
system or due to incomplete revascularization at the CABG. Later in the eighties, the reason for 
RECABG had shifted to predominantly failure of the graft. Furthermore, in the seventies the 
mean interval between the CABG and RECABG for graft failure alone was approximately 25 
months and 45 months for the combination of graft failure and progression of the atherosclerosis 
in the native coronary system. Later with more experience, these intervals increased up to 66 
months and 90 months respectively. These data indicate that even after a successful CABG, the 
patency of grafts is compromised predominantly by vein graft atherosclerosis. [12]  
Currently, the interval between the CABG and RECABG is still increasing because of the better 
patency of arterial grafts compared to vein grafts, and due to the acceptance of older patients for 
RECABG. [5,13] However, the use of arterial grafts will not hold back the process of 
atherosclerosis; it only prolongs the interval free of angina pectoris. As a result, the biphasic 
pattern will flatten because the early return of angina pectoris will decline and the late return will 
occur later. The need for a RECABG, therefore, cannot be abolished simply because the process 
of atherosclerosis cannot be stopped in spite of the use of arterial grafts and other precautions to 
improve the patency of the grafts.  
Another unexpected reason for an early return of angina pectoris is the popular ization of the off-
pump surgery. With the off–pump technique, the anastomosis are made on the beating heart with 
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the aid of special tools to stabilize the anastomotic region without hampering the heart function. 
It is a striking phenomenon that in several cardiac-surgery centers, with the off-pump technique, 
significantly less distal anastomoses, are performed compared to classic on-pump surgery. This 
incomplete revascularization could provoke an increase of predominantly early return of angina 
pectoris en thereby the need for a re-intervention e.g. a Percutaneous Transluminal Coronary 
Angioplasty (PTCA) or even RECABG. [14-17]           
 
Patient selection 
 
The two major indications for CABG are 1) improvement of the prognosis especially in 
patients with a significant stenosis of the ostium of the left coronary artery or the left main, three 
vessel disease with impaired left ventricular function and 2) relieve of complaints due to 
reversible myocardial ischemia not responding on medication. [18,19]  
For RECABG the indications for surgery are actually similar. Improvement of the prognosis 
after RECABG is especially seen in patients with late vein graft stenosis to the left anterior 
descending coronary artery (LAD) more than five years after CABG with revasculariztion of the 
LAD with the Left Internal Mammary Artery (LIMA)[20].  In the last two decades nearly all 
patients have received a LIMA graft to the LAD, so this cohort gradually has become rare. In 
patients with complaints not responding to medical treatment and proof of reversible myocardial 
ischemia, the indications for RECABG are thus similar as the indication for CABG [19] albeit 
that the perioperative mortality of the RECABG is higher (2-18%) compared to CABG (1-4%) 
[21-24] 
Although angiography is an important tool in evaluating coronary anatomy and status of the 
previous constructed grafts, it remains debatable whether the operability on the basis of the 
visualization of the coronary vessel alone is enough. To determine the diameter of the coronary 
vessels with angiography can be difficult, especially when these vessels are critically narrowed 
or totally occluded with insufficient perfusion.  
The mortality rate of emergency RECABG is high and varies between  25%-45%. [1-5,21-25]  It 
is, therefore, wise to avoid emergency RECAGB, as much as possible. [5] Medical therapy, intra 
aortic balloon counter pulsation (IABP) or even angioplasty of the culprit lesion can be used to 
stabilize these patients in order to perform the RECABG in a more stable situation. 
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Resternotomy. 
 
The risk of a resternotomy is related to fibrosis and scarring of the pericardium and 
mediastinum.[26] Hemorrhagic complications due to laceration of the right ventricle during 
resternotomy can be life threatening. In 1983, Loop concluded that control and management of 
the mediastinal adhesions, was the prime reason for the improved results in RECABG. [1] With 
increasing experience, repeat median sternotomy is no longer considered as an incremental risk 
factor for mortality for RECABG.[12] To avoid the potential problems of resternotomy, 
alternative approaches were introduced as an alternative to the resternotomy such as the 
posterolateral thoracotomy, [27] a left anterior small thoracotomy for minimal invasive 
procedures, [28] or even laparotomy  [29] These approaches have the advantage that they enter 
the chest by a non-operated route. However, the drawback is that they offer only a limited 
exposure of the heart, which can compromise total myocardial revascularization [30] Thus, a 
resternotomy is a demanding, challenging procedure and more than just reopening the chest.  
A point of discussion is if groin vessels must be exposed or not, and/or cannulated before 
resternotomy. In our department groin vessels are not exposed routinely, but are always checked 
before the sternotomy is performed. Exceptions are: second and third redo’s, patients with a 
history of sternal infection, grafts adherent to the sternum, IMA-grafts crossing the midline and 
patients with tricuspid valve regurgitation, and right atrial, ventricle dilatation, because a lesion 
to a dilated, thin right atrium or ventricle is difficult to repair.   
 
Grafts, old and new 
 
Certainly in RECABG, vessel identification can be difficult, and lack of bypass conduits 
may contribute to incomplete revascularization. Specific for RECABG is the presence of old 
vein grafts. Progression of atherosclerosis involves not only the native coronary artery system, 
but also the vein graft. A study from the Cleveland Clinic reported that 5 to12 years after CABG, 
40% of the vein grafts were stenotic or totally occluded.[31]  In spite of the use of antiplatelet 
medication which is said to delay this artherosclerotic process, the time of occurrence  remains 
unpredictable  [32]. Furthermore coronary angiography underestimates the severity of the 
atherosclerotic degeneration in vein grafts.[1-5]  
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Of clinical importance is that vein graft atherosclerosis is more dangerous than native vessel 
coronary artery disease. The mechanism by which late vein grafts occlude, produces clinical 
events such as embolization of atherosclerotic debris and graft failure. Furthermore it differs 
distinctly compared to native coronary artery atherosclerosis. Coronary artery atherosclerosis is 
focal, with eccentric plaques that have a fibrous cap overlying a center of lipid debris whereas 
vein graft atherosclerosis has not with the result that the debris is exposed directly to the blood 
stream. [33] These lesions are friable and fragile and might result in embolization by 
manipulations of the heart, arterial pressure fluctuations and antegrade delivery of cardioplegic 
solution during reoperations. [34,35]  It seems logical to speculate that naturally occurring 
embolization may account for unstable angina or myocardial infarction, due to the spreading of 
debris in the distal coronary arteries. This is also a reason for the high perioperative myocardial 
infarction rates and mortality rates in unstable RECABG patients.   
To decreases the risk of embolization during manipulation, the patient should be put on bypass 
with the so called ‘no-touch’ technique, retrograde delivery of cardioplegia and cardiac 
dissection when the heart is still and flaccid.  Ligation of diseased vein grafts is dangerous 
because this might result in squeezing debris to the distal coronary circulation. Some advocate 
graft division or favor replacement of the old vein grafts but even these options are debatable. 
[31,32,36]  
An argument against ligation or division of the old graft is the so-called 'hypoperfusion 
syndrome', This means that when a patent with a diseased vein graft to the LAD artery is 
disconnected and replaced by an IMA-graft, hypoperfusion of the coronary area might occur 
manifested as ST-segment changes, arrthymia or hypotension. This problem could be avoided by 
adding a new vein graft to the LAD, or with preservation of the old and diseased vein graft. [20]    
With the increased use of the IMA-grafts during CABG, reoperations in patients with a patent 
IMA-graft is challenging in terms of preservation of the patent IMA and myocardial protection 
of the IMA –dependent myocardium[37]. These problems can be adequately solved with the use 
of retrograde delivered cardioplegia. A patent IMA should not be considered as a risk factor for 
mortality or morbidity in reoperat ions. [5,13,37]  
Most RECABGs can be done using the classic conduits like the saphenous veins, the internal 
mammary arteries, the gastro-epiploic, radial and even the inferior epigastic artery. [38] 
Alternative conduits, used infrequently, are the lesser saphenous vein, cubital veins and 
homografts. The use of bovine heterograft arteries has now been abandoned due to unacceptable 
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low patency rates. In some patients however there will be just enough length of conduits, so that 
maximal use is important. Also Y- or T graft constructions can be performed. In patients with a 
patent IMA-graft, a recycling of this IMA graft can be done successfully without compromising 
this graft. This recycling technique was first described by the Nijmegen group. [39]      
 
Myocardial protection 
  
The mortality of a RECABG exceeds the mortality of a CABG [1-5,21-23]. Also, the 
difference between RECABG and CABG with regard to perioperative myocardial infarction is 
another striking finding. [1-5,21-23,40]  Furthermore in CABG, there is a shift away from 
cardiac-related postoperative morbidity and mortality in contrast to RECABG.  
The inefficiency of myocardial protection in RECABG is related to several problems. First, the 
complex anatomy, mostly expanded with a collateral circulation of the myocardial blood supply, 
the routes of myocardial perfusion with patent and diseased vein grafts, and the blood flow 
through patent IMA-grafts are the reasons that the antegrade delivered cardioplegia is suboptimal 
in protecting the heart. Secondly, embolization of debris from atherosclerotic vein grafts during 
antegrade infusion of cardioplegia jeopardizes the run-off of the distal coronary arteries which 
might lead to a perioperative myocardial infarction. In order to prevent this, one could argue that 
it might be wise to disconnect the diseased vein graft before cardioplegic delivery is given. The 
drawback with this option is that it might provoke hypoperfusion of the myocardium. Therefore, 
retrograde transatrial perfusion of cardioplegia through the coronary sinus seems to be the most 
effective alternative.[41,42]. The advantages are that there is no atherosclerosis in the venous  
system, the debris in the coronary arteries will be washed out and the cardioplegia can be 
delivered independently of the position of the heart. With this preservation technique, the 
Cleveland group has shown a significant decrease in perioperative myocardial infarction and 
postoperative morbidity thereby underscoring the effectiveness of the retrograde transatrial 
delivery of cardioplegia in RECABG. [40-43]. 
 
Perioperative mortality and morbidity 
 
Perioperative mortality and morbidity such as myocardial infarction after RECABG are 
still troublesome and higher than in CABG. Mortality rates vary between 4-18% for RECABG 
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versus 1-4% for CABG, and the incidence of perioperatieve myocardial infarction varies from 6-
15% in RECABG versus 2-6% in CABG [1,2,5,6,12,21-23] In 1987, Lytle et al [12] already 
mentioned these striking differences between CABG and RECABG. 
There is no doubt that advances in perioperative anesthetic management, myocardial protection 
and surgical techniques in the last decades have reduced the risks of RECABG. However, in 
spite of these changes, the prevalence of risk factors for hospital mortality and morbidity has 
further increased over the years [6,44,45]. A clearer insight into the demographic profile of the 
cardiac patients for RECABG is crucial to unravel the problem of a persistent high mortality and 
morbidity in RECABG [1,5,6,20,31,36-47]. Non-elective procedures, perioperative myocardial 
infarction and retrograde delivery of cardioplegia are all identified as independent variables for 
mortality and morbidity rates [5,6,40-52]. Still, it is difficult to compare these studies and come 
to a definitive conclusion because the endpoints ‘mortality’ an ‘morbidity’  are not defined 
consequently. Some series use in-hospital mortality and morbidity and others 30–days mortality 
and morbidity.  In our series we advocate a six months mortality and morbidity, because it is 
known that the operative risk, certainly in high-risk patients, is prolonged. [25, 53-55].     
 
Long-term results  
 
Ten-year survival after successful RECABG is about 80%. [5,20,21,48,50,51] A number 
of these patients return with symptomatic coronary disease, as coronary artery sclerosis is a 
progressive disease in both the native coronary system and the conduits. It is generally accepted 
that with each subsequent reintervention, the probability of an “angina-free period” as well as the 
interval between these periods diminish. [55]. The long-term results after revascularization of the 
coronary vessels are not only influenced by graft choice and completeness of the 
revascularization but also by older age, impairment of the left ventricle, hypertension, diabetes 
mellitus and congestive heart failure [5,20,49-52] For RECABG, it seems that the long-term 
results are predominantly determined by the perioperative risk and that survival of the 
postoperative period is the first step in long-term survival.   
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 Conclusion 
 
RECABG has become an increasing challenge for the cardiac surgeon. The increasing 
incidence of the procedure itself and the persistently elevated rates of morbidity and mortality all 
add to the challenge. RECABG is technically more complicated than CABG. Most of these 
complications are related to each other, and are the consequence of our strategies at the primary 
CABG. Therefore, at every RECABG, the cardiac surgeon may face the limitations of coronary 
artery bypass surgery.  
 
* On reoperations is based on the  article ‘The challenges of redocoronary artery surgery.’ by  L. Noyez published in 
Cardiology 2000;7:73-75. 
** Dr. Eric N. Robertson, Anesthesiologist, is thanked for his correction of the English text. 
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Abstract  
 
Objective: To Outline the changes of the patient population undergoing redo-coronary artery 
bypass surgery (RECABG).  
Methods: Preoperative data of 582 first RECABG's, January 1987- June 2000 were analyzed.  
Group A: 1987-1991 (n=193); group B: 1992-1995 (n=201); and group C: 1996- June 2000 
(n=188).  
Results: These 582 RECABG’s represent about 8.5% of the performed bypass surgeries during 
this period. Mean age (P=<0.001), percentage of patients with kidney disease (P=0.001), a 
preoperative PTCA (P<0.001) increased. Significant more elective operations (P<0.001) and 
lesser urgent operations (P=0.001) were performed in group C. There is a significant different 
distribution of vessel disease over the three periods (P=0.04). Significant more patients had a 
patent IMA graft (P<0.001). The angina-free period after CABG (P<0.001), the time period 
between both operations (P<0.001) and the period between the new onset of angina and the 
RECABG (p=0.012) increased significantly. Despite the importance of progression of 
atherosclerosis of any sort decrease significantly (P< 0.001) over the whole study, there is a 
significant increase of patients reoperated for isolated progression of the disease in the native 
coronary arteries (P<0.001) in group C. The impact of late graft failure was not different for the 
total group (P=0.82), however, the percentage of RECABG’s for isolated late graft failure 
increased significantly between group A and B (P<0.001) but there was a decrease from B to C, 
however, not significant (P=0.067). 
Conclusion: During the past years there is a trend in RECABG of older patients, with more 
coexisting disease. There are an increasing number of patients with patent arterial grafts, an 
increase of the event- free period after the CABG, the period between the CABG and RECABG 
and of the time period between the onset of new angina and the RECABG. Although the impact 
of atherosclerosis, as angiographic indication, decreased over the total group, there is the 
significant increase of the percentage of patients reoperated because of isolated progression of 
atherosclerosis in the native coronary arteries.    
 
Key words: 
Reoperation, Corona ry artery bypass, Atherosclerosis, Graft failure. 
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1. Introduction 
 
As in primary coronary artery bypass surgery (CABG), the patient's population 
undergoing first redo-coronary artery surgery (RECABG) has changed during the last years 
[1,2]. However, in the RECABG-population, also the changed strategies of primary myocardial 
revascularization take part in this evolution. The purpose of this paper is to study the 
evolutionary trends in the patient population undergoing RECABG. Therefore operative and 
postoperative data are only presented and discussed in relation to this changes.  
 
2. Material and methods  
 
2.1 Patients 
With the aid of our database, Coronary Surgery Database Radboud Hospital (CORRAD), 
a registry that stores pre-, peri-, postoperative data as well as follow-up data on all patients 
undergoing myocardial revascularization, we identified a series of 582 patients undergoing a 
RECABG from January 1987 to June 2000. The total group was subdivided into three time 
cohorts: group A (193 patients) operated between January 1987 and December 1991, group B 
(201 patients) operated between January 1992 and December 1995, and group C (188 patients) 
operated between January 1996 and June 2000.  
Table 1 presents the studied general variables. Diabetes was defined when there was diet-
controlled, oral therapy or insulin dependency. Hypertension was defined as systolic blood 
pressure of greater than 160 mmHg or diastolic pressure of greater than 100 mmHg. 
Hyperlipidemia was defined as having a total cholesterol level of greater than 250 mg/dl or a 
triglyceride level of greater than 200 mg/dl. Cerebrovascular disease was registered in patients 
with cerebrovascular accidents and/or transient ischaemic attack in their histories. Kidney 
disease was defined as having a documented renal failure (creatinine ³ 150 mmol/l), preoperative 
dialysis, or renal transplantation. Lung disease was registered in patients with chronic obstructive 
pulmonary disease, and/or a history of previous lung disease. Successful PTCA was defined as a 
successful PTCA as well before the CABG as before the RECABG. Impaired left ventricular 
function was noted when there was an ejection fraction of £ 30 %. It must be noted that ejection 
fraction is not routinely calculated for all patients, however for patients with bad ventricular 
function, this is mostly done.  
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Table 1. General preoperative variables  
Variable Group A Group B Group C P-value  
 N=193  (%) N=201  (%) N=188  (%)  
Sex    0.31 
  Men  148  (77) 165  (82) 154  (82)  
  Women 45  (23) 36  (18) 34  (18)  
Age (mean ± S.D.) (years) 60 ± 8.7 64 ± 7.8 66 ± 8.3 <0.001 
  Range 32 - 91 35 - 83 45 – 82  
Diabetes  26  (14) 41  (20) 36  (19) 0.16 
Hypertension 123  (64) 135  (67) 100  (53) 0.01 
Hyperlipidemia  112  (58) 126  (63) 105  (56) 0.37 
Family history of cardiovascular disease 133  (69) 122  (61) 102  (54) 0.01 
Peripheral vascular disease 37  (19) 50  (25) 42  (22) 0.39 
Cerebrovascular disease 11  (6) 15  (7.5) 15  (8) 0.65 
Kidney disease 1  (0.5) 5  (2.5) 14  (7.4) 0.001 
Lung disease 33  (17) 46  (23) 33  (18) 0.26 
Previous successful PTCA 19  (10) 22  (11) 47  (25) <0.001 
Myocardial infarction     
  Before the CABG 122  (63) 129  (64) 109  (58) 0.40 
  Between CABG and RECABG 46  (24) 62  (31) 49  (26) 0.27 
Impaired left ventricular function 3  (1.5) 5 (2) 4 (2) 0.3 
Clinical indication    0.006 
  Elective 96  (50) 93 (46) 122  (64) <0.001 
  Urgent 79  (41) 82  (41) 47  (25) 0.001 
  Emergency 18  (9) 26  (13) 19  (11) 0.6 
Vessel disease    0.04 
  One-vessel 12  (6) 9 (4) 17  (9) 0.18 
  Two-vessel 39  (20) 21  (10) 31  (17) 0.04 
  Three-vessel 142  (74) 171  (86) 140  (74) 0.007 
 
Clinical indication for RECABG was angina and proven ischemia (treadmill test, sintigraphy) 
despite medical therapy with b blockers, calcium antagonists or nitrates, or a combination.  
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We distinguish three groups. Elective operations, patients with stable cardiac function, usually 
scheduled at least one day prior to the surgical procedure. Urgent operations, when surgery is 
required within 24 hours after admission. Emergency operations: in case of operation for 
evolving infarction, ischemia not responding to medical therapy, or cardiogenic shock.  
Vessel-disease is also presented in Table 1. Important is that, in case of a diseased native 
coronary artery with a patent, not diseased, graft, this coronary artery was not coded as a 
diseased vessel. So a patient with a patent IMA-graft on a diseased LAD, and an occluded 
circumflex- and right coronary artery without, or with diseased grafts is registered as a two-
vessel disease.  
 Table 2 presents the specific RECABG variables. Patent internal mammary artery graft 
(IMA), and different time periods. The angiographic indication for RECABG is divided in five 
groups. Early graft failure, as documented graft failure within the first six months after the 
CABG. Late graft failure (GF), graft failure later than six months after CABG. Progression of 
athersoclerosis in the native coronary artery system (PA). The combination of GF and PA, and 
incomplete revascualarization, in case of a documented not- or wrong-bypassed vessel during the 
CABG. 
 The presented mortality is the hospital mortality, defined as the operative mortality and 
mortality during hospital stay after RECABG, independent of the time.  
 
2.2 Surgical technique 
 Our surgical technique is described in previous papers [3,4]. Of the total number of 
patients 79% (459/582) received at least one new arterial graft. In group A, 80% (154/193), 
group B, 82%  (164/201) and in group C, 75 % (141/188). Table 3 present the total number of 
new grafts and distal anastomoses, new arterial and vein grafts performed in the different groups.      
 
2.3 Statistical analysis 
The characteristics of patients in group A, B, and C is presented as percentages for 
dichotome variables and as mean ± S.D. for age, and time intervals. Differences between the 
groups were tested with F-test (one way analysis of variance) or with the c2 -test when 
appropriate.  Statistical significance was assumed at P £ 0.05.  
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Table 2.  Specific preoperative variables  
Variable Group A Group B Group C P-value  
 N=193  (%) N=201  (%) N=188  (%)  
Patent IMA 11  (6) 26  (13) 55  (30) <0.001 
Angina-free period after CABG (months)    <0.001 
  Mean ±  S.D. 68.2 ± 51.6 90.0 ± 50.8 108.7 ± 61.2  
  Range 0- 240 0 – 246 0 - 276  
Time between CABG - RECABG (months)    <0.001 
  Mean ±  S.D. 90.3 ± 52.9 118.5 ± 53.4 140.6 ± 61.3  
  Range 0 - 300 0 – 276 0 - 283  
Time between return of angina and RECABG 
(months) 
   0.012 
  Mean ±  S.D. 22.0 ± 24.4 28.4 ± 30.4 31.1 ± 36.8  
  Range 0 - 144 0 – 140 0 - 188  
Angiographic indication     <0.001 
  Early graft failure 18  (9) 16  (8) 9  (5) 0.2 
  Late graft failure 17  (9) 68  (34) 48  (26) <0.001 
  Progression of atherosclerosis in the native 
system 
10  (5) 13  (6) 36  (18) <0.001 
  Incomplete revascularization 3  (2) 3  (1) 1  (1) 0.6 
  Combination of GF and PA 145  (75) 101  (51) 94  (50) <0.001 
GF: Graft failure, PA: Progression of atherosclerosis in the native coronary artery system 
 
Table 3. Distribution of new constructed grafts  (no significant difference) 
Variable Group A Group B Group C 
Number of  N=193   N=201   N=188   
New constructed grafts 2.4 ± 0.8  (1 – 5) 2.6 ± 0.8  (1 – 5) 2.1 ± 0.8  (1 – 4) 
New constructed distal anastomoses 3.0 ± 1.2  (1 – 6) 3.3 ± 1.2  (1 – 7) 2.9 ± 1.3  (1 – 6) 
New arterial grafts 0.9 ± 0.3  (0 – 2) 1.2 ± 0.3  (0 – 2) 0.8 ± 0.5  (0 – 2) 
New vein grafts 1.5 ± 0.7  (0 – 4) 1.7 ± 0.3  (0 – 4) 1.5 ± 0.6  (0 – 4) 
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3. Results 
  
The 582 RECABG-patients represent 8.5% (582/6837) of the performed myocardial 
revascularizations during this time period. There is a difference, not significant (P=0.6), between 
the three time periods, group 193/2254 (8.5%) group B 201/2020 (9.9%) and 7.3% ( 188/2553) 
in group C. The overall mortality is 42/582 patients (7.2 %). There is a no statistical significant 
difference (P=0.07) between the three groups, group A; 11 % (21/193), group B; 6.4 % (13 
/201), group C; 4.2% (8/188). However, the decrease from 11% in group A to 4.2% in group C is 
statistical significant (P=0.03). 
Table 1 shows that there is a statistical significant increase of the mean age of the patients 
(P<0.001), with the significant step from group A to group B. The percentage of patients with 
kidney disease (P=0.001) increased significantly over the whole studied period and the 
percentage of preoperative successful PTCA (P<0.001) increased significantly from period B to 
C. On the other hand there is a significant decrease of patients with a family history of 
cardiovascular disease (P=0.01) during the whole period, and in the last period a decrease of 
patients with hypertension (P=0.01). 
There is no statistical significant difference in the percentage of diabetes, hyperlipidemia, 
peripheral vascular disease, cerebrovascular disease, lung disease, the occurrence of myocardial 
infarctions and percentage of patients with an impaired left ventricular function.  
There is a significant difference  (P= 0.006) in the clinical indication for RECABG, this 
statistical significance is due to the significant decrease of urgent patients in the last period (25% 
versus 41% in group A and B, P=<0.001) and consequently an increase of elective patients in 
group C (64% versus 50% and 46% in group A and B, P=0.001). The percentage of emergency 
RECABG, remains about 10% during the study.   
There is a statistical significant difference in the distribution of the vessel disease over 
period (P=0.04). There is an increase of patients operated for one vessel disease during period C 
(9% versus 6% and 4%), however not significant. The decrease of patients operated in period B 
is statistical significant (P=0.04) and also the higher number of patients operated for three vessel 
disease in period B is statistical significant different from the other two periods. (P=0.007) 
   Table 2 presents the specific RECABG variables. There is a significant increase of 
patients with patent arterial grafts, IMA-graft (P<0.001). Also, the angina- free period after the 
primary operation (P< 0.001), the time between CABG and RECABG (p<0.001), and also the 
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time period between the new onset of angina and the RECABG (p=0.012) increased 
significantly.  
There is a statistical significant difference in angiographic indication over the years. 
Analyzing the different classes of angiographic indication, there is a decrease, not significant 
(P=0.22) of patients operated for early graft failure (5% in group C versus 9% and 8%) There is a 
statistical significant (P<0.001) increase of patients reoperated for late graft failure in group B 
and C versus group A (34%, 26% versus 9%), The decrease of group C (26%) did not reach 
significance (P=0.067) versus the 34% in group B. There is a statistical significant increase (P< 
0.001) of patients operated for progression of atherosclerosis in the native coronary arteries (18% 
in group C versus 5% and 6%). Since period A there is a statistical significant decrease 
(P<0.001) of patients reoperated for combined graft failure and progression of atherosclerosis in 
the coronary arteries (75% in group A versus 51% and 50%). The percentage of patients operated 
for incomplete revascularizations remains small (1%) and was not different over the years.  
Analyzing the patients reoperated for progression of atherosclerosis of any sort, there is a 
statistical significant difference (P=<0.0001) over the studied period. The decrease from 80% 
(155/193) in group A versus 57% (114/201) in group B and versus 69% (130/188) in Group C is 
significant (P=0.001 A-B, P=0.01 A-C). However, the increase from B to C is also significant 
(P=0.01). For late graft failure of any sort, there is no statistical significant difference over the 
study (P=0.82). The increase from 84% (162/193) in group A versus   89% (169/201) in group B 
is not significant (P=0.1), the decrease from 89% in group B to the 76% (142/188) in group C 
reaches statistical significance (p=0.02).   
There is a decrease (from 80% to 75%), however, not significant (P=0.7) of patients 
receiving a new arterial graft. The number of new grafts, distal anastomoses, new arterial and 
venous grafts is not statistical significant different (P=0.2) between the three groups (table 3).  
  
4. Discussion 
 
It must be clear that the aim of this paper is to outline the changes in the population of 
patients undergoing RECABG over the years. The number of RECABG’s over the studied period 
remains stable; the decrease in the last period is not significant. It is known that RECABG has a 
higher mortality than CABG [3,5,6]. Despite there is not a significant decrease of the mortality 
over the studied period, our mortality of the last period 4.2% is statistical significant lower than 
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the 11% of the first studied period (group A). Mortality is not an endpoint in this paper, however, 
since our and other previous studies identified –urgent and emergency RECABG- as dominant 
predictors of mortality, [3,5,6] we avoid to do urgent/emergency RECABG.  The statistical 
significant decrease of urgent RECABG, in this study is certainly one, and an important one, in 
the decrease of mortality in the last studied period.[3]  
As in CABG, the trend to operate older patients with more coexisting disease, is also 
visible in the RECABG population [1,2]. There is an increase of age in our study (group A 
versus B and C). That this increase of age is not continuous over the whole studied period can be 
related to several factors. There is use of arterial grafts during CABG, even in elderly patients, 
since the eighties. [7] Because these older patients received arterial grafts, at the CABG, the 
event-free period after CABG increased, which means that they were even older at the moment 
of the RECABG. It is certain that older patients are not so frequently presented for RECABG, or 
died already before, because of their age and before we have a statistical significant increase of 
the mean age of a group, we need a lot of older patients in this group. There is a significant 
increase of patients with kidney disease That there is an increase of patients with kidney disease 
undergoing CABG the last decade is known, and this is also a result of the aging of the patient 
population. [8] There is a significant increase of successful PTCA's over the studied period 
(group C). This is similar as in CABG [2], and we know that a lot of patients underwent a PTCA 
between CAGB and RECABG. Our strategy, to stabilize urgent/ emergency patients, eventually 
by PTCA of the culprit lesion, is probably one of the reasons for this increased percentage in 
group C.  However, because this is not registered separately, we cannot prove that there is a 
specific increase of PTCA between CABG and RECABG.  
The percentage of patients with hypertension and a family history of cardiovascular 
disease decreased significantly. Hypertension is a comorbidity factor with an incremental risk for 
death in the late phase (more than 6 years after CABG), so because the increase of the time 
between the CABG and the RECABG, more than 10 years in group C, [9] a number of patients 
with hypertension died already. 
It may be remarkable that there is a slight, not significant, increase of patients with 
diabetes (14% to 19 %), and cerebrovascular disease (6% to 8%). Here again we can suppose 
that a several of these patients died already, due to this comorbidity.  But probably a lot of these 
patients were even not presented for RECAGB, because of the perioperative risk for morbidity 
and mortality. Diabetic patients have mostly diffuse and distal pathology, not so suitable for 
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surgery and diabetes is also a risk factor for perioperative myocardial infarction and mortality in 
RECABG. [3] Also patients with a history of a cerebrovascular disease have a higher risk for 
neurological morbidity during cardiac surgery. [10]  
So, the increase of co-morbidity with RECABG seems to be of lesser importance than in 
CABG. However, it must be clear, that the RECABG population is only a part of the population 
with an insufficient result of the CABG. Some of them died already, due the importance of 
several co-morbidity factors over the years, or were not presented for RECABG, because they 
have not enough symptoms, can be managed with medica tion, by interventional procedures, or 
because the procedural risk seems to high in relation with the expected benefit. On the other 
hand, because of the interval between CABG and RECABG, we can expect a further increase of 
co-morbidity variables in the RECABG-group over the years. If we compare our series of CABG 
between 1987 and 1995 we note an increase of patients with diabetes, and these with 
cerebrovascular disease in particular in the years 1992-1995 [2].  The interval between CABG 
and RECABG at this moment is about 12 years, so some of these patients will be reoperated over 
about five years.  
There is no significant difference in myocardial infarct percentage before CABG or 
between CABG and RECABG, neither of the percentage of patients with an impaired left 
ventricular function, over the years.  
There is a significant difference in the clinical indication for RECABG, especially a 
significant decrease of urgent RECABG, and an increase of elective RECABG (group C). Since 
our study identifying urgent and emergency RECABG, [3] as dominant independent variables in 
predicting the occurrence of a perioperative myocardial infarction and mortality, we try to avoid 
urgent- emergency RECABG since 1996.  The number of emergency RECABG, is constant over 
the studied period (10%), this were patients that we could not stabilize.   
   There is a significant difference in vessel disease over the studied periods. Because of the 
complex blood supply of the myocardium by native coronary arteries, grafts, collaterals, it is 
sometimes difficult and arbitrary to distinguish one-two- three vessel disease in redo-patients. 
Therefore our specific registration of one-two-three-vessel disease in redo-patients as already 
defined, and also this is the reason why we do not register left main in these patients.[3] The 
percentage of patients undergoing RECABG for one -vessel disease is low, and remains stable 
over the years (P=0.18) The statistical significant difference in vessel disease is caused by the 
significant lower percentage of patients with two vessel disease and the higher percentage of 
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patients with three-vessel disease in group B versus A and C. However there is a different reason 
for the trend seen from A to B and the trend from B to C. That in group C a lower percentage of 
patients is reoperated for three-vessel disease is certainly related to the use on arterial grafts. 
Most patients received at the CABG an IMA-graft to the LAD. The percentage of about 30 % of 
patients with a patent IMA in group C (table 2) is corresponding well with 74% of patients 
reoperated for three-vessel disease.  Also in group B the percentage of 12% patients with a patent 
IMA graft is complementary to about 86% patients reoperated for three-vessel disease. In group 
A, there are only a small number of patients with a patent IMA-graft at the moment of the 
RECABG. But about 25% of the patients were reoperated for early/late graft failure, progression 
of atherosclerosis in the native coronary arteries, and incomplete revascularization (table2). 
Several of these patients had patent venous grafts at the moment of the RECABG and were 
therefore not registered as three-vessel disease. 
 Despite the significant difference in vessel disease of the three groups, there is no 
statistical significant difference in the number of new constructed grafts or distal anastomoses 
(table 3). The reason is that the percentage of patients with two-and three-vessel disease remains 
quit stable over the three periods, the higher number of distal anastomoses in group B is an 
indication that more vessels were bypassed (not significant).   
 The statistical significant increase of a patent IMA is of course a result of our own 
surgical work. The effect of an internal mammary artery graft on survival and the event-free 
period after CABG is well known. [11] The significant increase of angina- free period, time 
interval between CABG and RECABG confirms this. The group of patients undergoing 
RECABG with a patent arterial graft offers a double challenge: the problem of protection in the 
myocardial region supplied by the arterial graft, and the preservation of the patent arterial graft. 
Certainly because preservation of a patent arterial graft results in a decrease of morbidity and 
mortality of the RECABG, but damage of this arterial graft results in  a increase of morbidity and 
mortality of RECAGB [12]. Despite surgeons experienced in performing RECABG, who are 
used to handling patent arterial grafts, this challenge can be partially responsible for the slight, 
but significant, increase of the time period between the new onset of angina and the RECABG, 
because several people are more conservative in patients with return of angina but with (a) patent 
arterial graft(s), mostly an internal mammary graft to the anterior site. [13] 
Despite the significant higher percentage of patent IMA-grafts over the years, the number 
of patients receiving a new arterial graft, and the number of new constructed arterial grafts did 
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not change. This is because in a lot of patients with one patient arterial graft a second new, 
mostly the right IMA, but also the gastroepiploic artery is used. In some patients a patent IMA 
graft is recycled to another vessel [4,14]. 
The percentage of patients reoperated for early graft failure and incomplete 
revascularization decreased, not significant, over the years, but is a small percentage.  
On the whole, there is a decrease of patients re-operated for progression of atherosclerosis 
of any sort. The high, and statistical significant (P<0.001) percentage of patients in group A, 
reoperated for progression of atherosclerosis of any sort in combination with graft failure, is 
partially explaining the global decrease. However, further analysis shows a statistical significant 
increase for patients reoperated for atherosclersosis of any sort in group C versus group B, and 
this is only related to the increase (P<0.001) of patients reoperated for isolated progression of the 
disease in the native system. There is no statistical significant difference in the percentage of 
patients reoperated for late graft failure of any sort (P=0.82). That there is no significant 
difference between group A and B, despite there is an statistical difference for patients 
reoperated for the combination of graft failure and progression of atherosclerosis, is due to the 
statistical significant increase (P<0.001) of patients reoperated for isolated late graft failure in 
group B. That the decrease of patients reoperated for late graft failure of any sort between group 
B and C reaches significance (P=0.02) is due to the complementary effect of the decrease of 
isolated late graft failure (P=0.06) and in combination with progression of atherosclerosis in 
group C. These results are interesting, in group B, there is a high percentage of patients 
reoperated for isolated late graft failure, we can suppose that these patients had an initial good 
revascularization, however due to the vein graft pathology they need a reoperation. This in 
contrast with group A, were a lot of patients were reoperated for combined graft failure and 
progression of atherosclerosis, but significant shorter after the CABG. This trend was already 
described by Lytle et al. [15] In group C, there is a significant decrease of patients reoperated for 
isolated late graft failure (P=0.02), this is due to extensive use of arterial grafts during the CABG 
(patent IMA = 30%) and probably also to the use of platelet- inhibiting medication [16], this 
evolution is also reflected in the increased time between CABG and RECABG. However, there 
is in group C a significant increase of patients reoperated for progression of atherosclerosis of 
any sort, but as a consequence of the increasing number of patients reoperated for isolated 
progression of atherosclerosis in the native coronary arteries (P<0.001). This means that despite 
surgical evo lution, the increasing use of arterial grafts, certainly resulting in an increase of the 
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event-free period, and increasing the time before a RECABG, the disease is still going on. The 
knowledge that in group C, we have patients with total arterial revacula rization at the CABG, 
and new lesions in native coronary arteries, in some patients, even distal of a patent arterial graft, 
let us suppose that total arterial revascularization is not excluding RECABG. These RECABG's, 
with several patent arterial grafts, offer again new surgical challenges: preservation of the arterial 
grafts, mobilization of the heart, recycling of arterial grafts, use of veins, or other alternative 
grafts.    
 
In conclusion there have been, during the last years, an increasing number of older 
patients, with more coexisting disease, and more patent arterial grafts, undergoing RECABG. 
This is not only due to demographic changes, but also in part the result of the different strategies 
used at the CABG. The extensive use of arterial grafts at CABG, results in an increase of the 
event-free period and of the period between CAGB and RECABG. The increasing number of 
patients reoperated for progression of the disease in the coronary arteries, confirms again the 
palliative aspect of bypass surgery and in our aging population, we can expect a further increase 
of this trend. 
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Abstract  
 
Objective: Analysis of short- and long- term results, clinical- functional- and subjective status of 
patients, with a patent arterial graft, after RECABG. 
Methods: Perioperative and follow-up data of 71 patients, undergoing RECABG  (1987 – 1998) 
were studied. A cross-sectional follow-up was conducted, functional evaluation by the Duke 
Activity Status Index  (DASI), and patients evaluation of his life situation were registered. 
Results: Perioperative mortality was 7%. Eleven patients died during follow-up. The 12-month 
and 60-month survival was 96% and 80%. Event-free survival was 86% and 51%. Family 
doctors declared that 55/66 (83%) had benefit of the RECABG. NYHA decreased significantly 
from 3.4±0.5 preoperative versus 1.5±0.4 postoperative. The mean DASI was 38.06±10.42. At 
the moment of the cross-sectional follow-up, 45/ 55 patients (82%) declared to have a benefit of 
the RECABG.  
Conclusion: Improvement in NYHA-class, good postoperative functional capacity, and patients 
positive evaluation, justify RECABG in patients with a patent IMA graft.  
 
Key-words 
 
Coronary reoperations, Internal mammary artery, Mortality, Morbidity, Functional evaluation, 
Follow-up. 
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Introduction 
 
The number of coronary reoperations (RECABG) continues to increase. Despite this, 
RECABGs have higher perioperative mortality and also at long term the results, mortality, return 
of ischemic events are higher than in patients undergoing a primary myocardial revascularization 
(CABG) [1-4]. Moreover, there is a good survival ra te with a patent arterial graft, with only a 
recuurence of angina without reintervention [5,6]. This makes that the decision between medical 
treatment and RECABG for this group of patients is difficult.  
In this study we evaluate short- and long- term the results, clinical- functional- and 
subjective status of patients, with a patent arterial graft, after RECABG. 
 
Patients and Methods 
 
Patients 
We took our information from the Coronary Surgery Database-Radboud Hospital 
(CORRAD), which is a registry that stores pre-, per-, and postoperative (in hospital) data 
regarding all patients undergoing isolated myocardial revascularization, we identified a 
consecutive series of 71 patients, with a patent IMA-graft, undergoing a RECABG from January 
1987, through December 1998.  During the same time cohort 6083 isolated myocardial 
revascularizations were carried out, 590 (9.7%) were first RECABG, so these 71 patients 
represent 12% of the total number of first RECABG’s performed at our institution.  
Table I. shows the preoperative data of the studied patient group. This was concluded by 
carrying out the following tests. Diabetes mellitus was detected with a positive glucose tolerance 
test, peroral antidiabetec medication or insulin dependency, Hypertension was defined as systolic 
blood pressure > 160 mmHg or diastolic pressure > 100 mmHg. Hyperlipidemia was defined as 
total cholesterol level > 6.4 mmol/L or triglyceride level > 2 mmol/L, and renal dysfunction as a 
creatinine level > 150 mmol/L or preoperative dialysis. Neurological pathology was registered in 
patients with a cerebrovascular accident and/or a transient ischemic attack in their history. 
Pulmonary pathology was registered in patients with chronic obstructive pulmonary disease, 
and/or a history of previous lung d isease. 
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Table I. Preoperative data 
Variable No. of 
patients  
(n= 71) (%) 
Sex  
  Men    50  (70) 
  Women   21  (30) 
Age (mean±S.D.) (years)   62±8.29 
  Range   45 – 82 
Diabetes   18  (25) 
Systemic hypertension   48  (68) 
Hyperlipidemia    42  (59) 
Family history of cardiovascular disease   53  (76) 
Peripheral vascular atherosclerosis   17  (10) 
Neurological pathology    4   (5.5) 
Renal dysfunction    5   (7) 
Pulmonary pathology  11   (15) 
  
Myocardial infarction  
  Before the initial operation  39  (55) 
  Between the initial and the reoperation    9  (12.5) 
PTCA  18  (25) 
  
Mean interval (±) S.D. between the operations (mos)  70±54,5 
  Range 1 – 180 
 
The localization of the used IMA-grafts at the initial operation is summarized in Table II. 
In 66 patients one IMA was used, in five patients both IMAs were used. One patient with a left 
IMA to the left anterior descending coronary artery (LAD) and the right IMA to the circumflex 
coronary artery (CX), two patients with the left IMA to the LAD and the right IMA to the right 
coronary artery (RC), and two patients with the left IMA to the CX and the right IMA to the 
LAD.   
 
Table II. Localisation of the used IMA-grafts at the initial operation. 
Localisation Left IMA Right  IMA 
LAD 56 3 
LAD-D 3  
CX 10 1 
RC  3 
IMA: internal mammary artery, LAD: left anterior descending coronary artery, D: diagonal branch, CX: 
circumflex coronary artery, RC: right coronary artery. 
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Indications for reoperation 
The clinical and angiographic indication is summarized in Table III. The clinical 
indication in all patients was angina of at least New York Heart Association (NYHA) class III 
despite medical therapy with b blockers, calcium antagonists or nitrates, or a combination.  
 
Table III. Clinical and angiographic indication for reoperation 
Variable  Patients 
n=71  (%) 
Clinical indication  
  NYHA < IV   39  (55) 
  NYHA = IV   29  (41) 
  Emergency    3   (4) 
  
Angiographic indication  
  Graft failure  23   (32) 
  Progression of atherosclerosis in native coronary vessels  14   (20) 
  Late graft failure and progression of atherosclerosis in native  
coronary vessels 
 31   (44) 
  Incomplete revascularisation    3    (4) 
NYHA= New York Heart Association 
 
Patients with angina at rest were registered as NYHA=IV, and patients with ischemia not 
responding to medical therapy, as emergency operation. The mean NYHA for the total group 
was 3.4±0.5 (3-4). Twelve patients (17 %) were operated for a single vessel, 15 patients (21 %) 
for two vessels, and 44 patients (62 %) for  three vessel disease. Forty- four patients (66 %) had 
preoperatively a sinus rhythm and 1 patient had a left ventricular ejection fraction below 30%.  
 
Surgical technique  
Sixty-four (90 %) patients were operated using standard cardiopulmonary bypass, as 
described in a previous paper [7]. Three patients (4.5 %) were put on bypass, and were operated 
on an empty beating heart without aortic-cross clamping, and 4 (5.5 %) patients were operated 
on a beating heart without use of the cardiopulmonary bypass.  
For the patients operated on with cardiopulmonary bypass the mean bypass time was 
149.8 ± 81,2 minutes (range 46-485), and the mean duration of aortic cross-clamping was 65.8 ± 
43.0 minutes (range 15-227). Myocardial protection during aortic cross-clamping was performed 
with cold (4°C) St.Thomas’Hospital cardioplegia, and since 1995 with blood cardioplegia. In 48 
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(77 %) cardioplegia was delivered initial retrograde, in 14 (21%) patients antegrade. Two 
patients (2%) were operated using the technique of intermittent aortic cross clamping.   
At reoperation there was a mean of 1.8 ± 0.8 (range 1-4) grafts, and 2.1 ± 1.0 (range 1-5) distal 
anastomoses constructed. Thirty-six new arterial grafts were constructed. The left IMA was used 
for 14 grafts (39 %), the right IMA for 19 grafts (53%) and the gastroepiploic artery for 3 grafts 
(8 %).  In 14 patients (20%) we recycled the left IMA graft [8], 6 times to the anterior 
descending coronary artery, 8 times to the circumflex coronary artery with a right IMA to the left 
anterior descending coronary artery.  
 
Follow-up 
The follow-up of all cardiac patients is registered in our follow-up databank. This 
databank contains reports of referring cardiologists and family doctors, mostly medical 
information, For the studied group cross-sectional follow-up was conducted in December 1998, 
at that time an additional functional evaluation by the Duke Activity Status Index (DASI) and 
information was obtained by telephone contact with the patients and their family and their family 
doctor. The DASI is a 12- item questionnaire that determines a patient’s ability to participate in a 
spectrum of activity without difficulty and correlates strongly with maximal oxygen 
consumption during exercise, and this index has been validated in patients with several cardiac 
disorders [9]. All patients and their family doctors were asked to answer the question “are you 
feeling better, worse and is there improvement since the RECABG.?”  
 
Statistical analysis 
Data are presented as frequency distribution and percentages. Values of continuous 
variables are expressed as mean±S.D. Data were analyzed with the Student’s t test and the chi-
square test. Survival curves and event- free survival were obtained by the method of Kaplan 
Meier. Statistical significance was assumed when the p value was less than 0.05. 
 
Results 
 
During the 12 years of the study, the number of RECABGs with a patent IMA-graft 
increased significantly from 0% during the time cohort ‘87-’89 over 8.1% in the time cohort ‘90-
’92, 12% in the time cohort ‘93-’95, to 28% in the time cohort ‘96-’98 (p< 0.05) (figure 1). 
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Figure 1. Distribution of the reoperations over four time cohorts (p<0.05 for the trend).  
 
 In 6 patients the arterial graft was damaged, five times a left IMA and one right IMA 
pedicle, cross ing the median line. In all these patients the pedicle was not covered with 
pericardium and was adherent to the sternum. The perioperative mortality (operative and hospital 
mortality) was 7 %  (5/71). Perioperative myocardial infarction (defined as new pos toperative Q 
waves or T wave changes accompanied by increased cardiac enzymes) occurred in 8 patients and 
was the major cause death in 3/5 patients. The other postoperative morbidity is presented in table 
IV.     
 
Table IV. Postoperative morbidity 
Variable No. of patients 
(n=71) 
Ventilatory support > 2 days  1 
Reoperation for bleeding and other problems 10 
Sternal wound problems 1 
Neurological problems 0 
Nefrological problems 1 
Pulmonary problems  7 
 
The follow-up of the 66 hospital survivors was complete. The mean survival time was 
88,5±5.5 months. And the actuarial survival of the hospital survivors is presented in figure 2. At 
12 months the survival was 96%, at 36 months 88% and 80% at 60 months. Family doctors 
declared that 55/66 hospital survivors were better after the RECABG than before. During follow-
up 11 patients died, 9 deaths were cardiac related, 2 were not cardiac-related. Figure 2 present 
also the event- free actuarial curve of these patients. The first ischemic event is defined as return 
of angina; cardiac related death, a new myocardial myocardial infarction, new arrhythmia, 
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congestive heart failure, and an intervention for angina. The event- free group at 12 months was 
86%, at 36 months 70% and at 60 months 51%.  
 
Figure 2. Actuarial and event-free survival 
 
The registered first ischemic events were presented in Table V.  
 
Table V. First ischemic events  
Variable No. of patients (n=66)  
Myocardial infarction  2 
Rithm problems 2 
Dyspnae 12 
Return of angina 12 
PTCA 1 
RE-RE-CABG 2 
 
The 55 patients at the moment of the cross-sectional follow up, there is a statistical 
significant improvement of NYHA classification for the total group, preoperative 3.4±0.5 versus 
1.5±0.4 postoperative (p<0.05). Twenty- four patients (44%) were in NYHA class I, 20 patients 
(37%) in NYHA class II, 4 patients (7.2%) in NYHA III, and 1 patient (1.8%) in NYHA IV. The 
mean DASI was 38.06±10.42 with a range from 12.5 to 52.5. 
To the question: are you feeling better, worse, or is there no improvement since the 
REC ABG, 45 patients (82%) answered that they were better since the operation, 7 patients (13 
%) were feeling worse and 3 patients (5%) answered that there was no improvement. On the 
same question, but independently, the family doctors answered for 46 patients (83%) that they 
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were better since the RECABG, for 8 patients (14%) that they were worse, and for one patient 
(3%) that there was no improvement.  
 
Discussion 
 
 The number of RECABGs is still increasing. Vein graft atherosclerosis and progression 
of atherosclerosis in native coronary vessels are the leading angiographic indication for 
reoperation. This progression of atherosclerosis takes mostly 10-15 years and is an indication 
that angina will return [1-4]. Angina, not responding with medical therapy, is the primary 
indication for RECABG. Only patients with late stenoses in saphenous vein grafts to the left 
anterior descending coronary artery has an improved late survival when this diseased graft is 
replaced by an arterial graft [10,11]. 
With the extensive use of arterial grafts since 1987 [12], there is less of a chance that 
angina will return, however, progression of atherosclerosis is not stopped. So more and more 
patients with a patent arterial graft (mostly to the LAD), with return of angina, are presented for 
RECABG. Important for this patient group is the knowledge that return of angina has minimal 
impact on survival [6] and RECABG has a high perioperative risk, and did not improve survival 
[5,1-4]. 
 In this study, perioperative mortality is 7%, which is comparable with other series 
reporting mortality rates between 3,5% and 12,5%  [1-4,13]. In this series, there was the specific 
problem of patients with a patent arterial graft. It is documented that a patent arterial graft is not 
a predictor of perioperative mortality [7,14,15].  However this patent arterial graft gives this 
RECABG a double challenge [16]. First this type of graft may not be damaged. In this series, 6 
IMA’s were damaged, al these pedicles were not covered by pericardium and adherent to the 
sternum. The placement and covering of the IMA-pedicle at the primary operation is essential 
[16]. The second challenge is myocardial protection of the area supply by the patent IMA. The 
use of retrograde delivered cardioplegia is advocated to reach this myocardium [14]. But 
retrograde delivery of cardioplegic solutions is important in RECABG, in order to prevent 
spreading of debris from diseased venous grafts; retrograde cardioplegia is a significant variable 
in avoiding perioperative myocardial infarction [7]. The use of other techniques, as intermittent 
aortic cross-clamping, or beating heart procedures may be helpful in specific patients.  Our group 
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first described the possibility of recycling a patent IMA in 1993, which was later confirmed by 
others [8,17-19].    
Our survival rate is comparable with other series and also our event-free survival rate 
[3,4,6,13]. Interesting is that the recurrence of angina is not the only important event, but also 
dyspnae, a sign of congestive heartfailure. More than 80% of the patients, however, declared to 
have benefitted from the RECAGB, what is confirmed by the family doctors. The significant 
improvement of the NYHA-class and the good functional status of these patients is confirmed by 
the DASI-result of 38,6±10.42 what is correlating with a maximal oxygen uptake of 
approximately 28 ml/min/kg, indicating a normal functional capacity [20].  
 
In conclusion, perioperative mortality, long-term survival and event- free survival of this 
group of RECABG are not different from other series with or without patent arterial graft. This 
confirms that a patent arterial graft is not an additional risk factor for the operation. The good 
clinical, functional and subjective status of the patients justify this RECABG in patients with 
unacceptable angina.  
 
*We thank Mrs. Lisette Peters for her work in the secretarial function of the CORRAD database. 
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Abstract 
 
Background.  Identify risk factors associated with mortality following repeat coronary 
revascularization (redoCABG) within the first 6 months following surgery. 
Methods .  Five hundred forty-one redoCABG patients (1987-1998) were studied by uni-  
and multivariant analysis.  Mortality was assessed at three different points: hospital mortality (A) 
(36/541, 6.7%); mortality at six months (C) 75/541, 13.9%); and outpatient perioperative 
mortality, which is a death occurring from the time of hospital discharge to six months 
postoperatively (B) 39/541, 7.2%). 
Results.  Diabetes, hypertension, peripheral vascular disease, renal insufficiency, lung 
disease, myocardial infarction (MI) before the first operation, MI between the first and 
redoCABG, lack of sinus rhythm, No- IMA-graft, acute/emergency operation, perfusion time, 
and perioperative MI were all identified as risk factors related to early mortality.  MI before the 
first operation, antegrade cardioplegia, and the time period 1987 to 1992 all influenced hospital 
mortality (A).  Diabetes, hypertension, renal insufficiency, lung disease, and valvular heart 
disease all influenced the outpatient mortality up to six months.  Independent predictive factors 
for early mortality were: age > 69 years; diabetes; vascular insufficiency; chronic lung disease; 
MI between first and redoCABG; No-IMA-graft; acute preoperative MI; emergency operation; 
perfusion time; perioperative MI; and the time period 1987 to 1992.  Risk factors for in-hospital 
death included MI between the first and redoCABG, cardiopulmonary bypass time, and the time 
period 1987 to 1992.  Diabetes is an important risk factor during the outpatient perioperative 
phase.  Emergency surgery and perioperative MI predict mortality regardless of the time period 
(A, B or C). 
Conclusion.  Early mortality after redoCABG is influenced by many variables during the 
first 6 months following surgery.  Understanding these factors and their time course may better 
help to assess the true risk associated with reoperation for recurrent coronary insufficiency.  
 
Key words :  Coronary reoperations;  Early mortality;  Hospital mortality 
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 Introduction 
 
Mortality after coronary reoperations (redoCABG) is still higher than for the initial 
revascularization procedure (CABG).  Several studies have attempted to analyze operative, 30-
day, and hospital mortality following coronary reoperations [1-8].  In reviewing these studies, 
there is no consensus as to predictors of early mortality.  The purpose of the present study is to 
identify risk factors for early mortality within the first six months following redoCABG, and also 
to analyze those risk factors and patient characteristics that may be associated with an increased 
risk following repeat revascularization.   
 
Materials and methods  
Patients 
 The Coronary Surgery Database at Radboud Hospital (CORRAD), a registry that stores 
pre-, peri-, postoperative follow-up data on all patients undergoing isolated coronary bypass 
surgery at the University Medical Center St. Radboud, Nijmegen (UMC St. Radboud) was used 
to identify 541 patients undergoing a first coronary reoperation (redoCABG) from January 1987 
to December 1998.  All patients underwent isolated coronary revascularization.  No patients with 
combined procedures were included.  A number of different variables were analyzed and are 
presented in Table 1.  A six-month period of follow-up was selected.  The information placed in 
our database is based on data from cardiologists, family doctors, and an annual survey sent 
directly to the patients.  In addition a cross-sectional follow-up was performed in the first months 
of 2000.  This follow-up was performed by a survey sent directly to the patients.  If there was no 
response from the patient, the information was traced by telephone contact with the patient, 
family, doctor, or government records.  The six-month follow-up in this study was 100%.  In 
case of death,  the cardiologist, family doctor, or patient's family was contacted to identify the 
cause of death. 
 
Perioperative and six-month mortality 
 Hospital mortality (A) was defined as an operative death or mortality at the University 
Hospital anytime during the hospitalization for the redo coronary artery bypass.  Six-month 
mortality (C) was defined as all mortality within the first six months from the time of surgery.  
This is consistent with the early phase mortality described by Blackstone [9].  Blackstone's study  
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Table 1.  Variables analyzed in patients undergoing reoperative coronary artery bypass. 
Age (years) 3 groups: age < 60, 60 ³ age <70, age ³ 70 years 
Sex Male, Female  
Obesity Body Surface Area (BSA) > 2.1 
Diabetes Diet-controlled, oral therapy or insulin dependent diabetes 
Hypertension Systolic blood pressure > 160 mmHg, or diastolic pressure > 100 mmHg. 
Or antihypertensive medication.  
Hyperlipidemia  Total cholesterol > 250mg/dl or triglyceride level 200 mg/dl 
Vascular disease Peripheral -, abdominal vascular pathology or operation 
Neurological disease Cerebrovascular accidents and /or transient ischemic attack 
Renal disease Renal failure (creatinine ³ 150 mmol /L) preoperative dialysis, renal 
transplantation 
Lung disease Chronic obstructive pulmonary disease and/or history of previous lung 
disease 
PTCA History of previous percutaneous transluminal coronary angioplasty 
Preoperative myocardial 
infarction (MI) 
History of myocardial infarction before the first operation 
Myocardial infarction (MI) 
between operations. 
History of myocardial infarction between the first operation and the 
reoperation. 
Rhythm Preoperative sinus rhythm 
Internal mammary artery 
graft (IMA-graft) 
Patent IMA graft at the reoperation 
Operative status 
3 groups: Elective: patients with stable cardiac function, usually 
scheduled at least one day prior to the surgical procedure. Urgent: 
surgery is required within 24 hours after admission, Emergency: 
operation for evolving infarction, ischemia not responding to medical 
therapy, or cardiogenic shock. 
Mild valve pathology Combined valve disease, not requiring surgical intervention 
ECC ECC: extra corporal circulation, duration in minutes 
AoX AoX; aortic cross clamp, duration in minutes 
Perioperative myocardial 
infarction (peri-MI) 
A new Q wave and a CPK-MB% ³ 10% 
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only describes mortality up to six months following the operation.  In addition, we defined 
outpatient perioperative mortality as the difference between the hospital- and six-month 
mortality (B). 
 
Discharge policy 
 Patients are either sent home or transferred to the referring cardiac center from UMC. St. 
Radboud Nijmegen.  Patients are not discharged or transferred unless they are ambulatory and 
require minimal levels of care.  The mean hospital stay the UMC St. Radboud for redoCABG is 
ten days.  Patients with postoperative complications such as wound problems remain at UMC St. 
Radboud until they are ambulatory and require minimal care.  Thus patients who died in the 
perioperative period were all in good condition and functioning at the time they were discharged 
from the UMC St. Radboud center.  In the 541 patients studied, all hospital deaths occurred 
within the first five months after surgery.  None of the deaths occurring during the post-discharge 
perioperative period died after transfer to their referring cardiac center and thus would not be 
considered a hospital death directly related to the surgery. 
 
Surgical technique 
 Our surgical technique has been described previously [7,8].  It is important to note that 
since 1993 cardioplegia has been delivered using retrograde techniques in redoCABG 
procedures.  Of the 541 patients, 230 (42%) patients had antegrade, and 305 patients (67%) had 
retrograde delivery of their cardioplegia.  Six other patients (1%) were operated without 
cardioplegic arrest (intermittent aortic cross-clamping; two patients, off-pump, four patients). 
 The mean bypass time was 140 ± 60.8 minutes (range 25-485), and the mean duration of 
aortic cross-clamping was 70 ± 33.6 minutes (range 10-227).  There were 2.4 ± 0.8 grafts (range 
1-5), per patient, and 3.2 ± 1.2 (range 1-7) distal anastomoses.  On average, 1.0 ± 0.6 (range 1-2) 
arterial grafts were used in the patients, and resulted in 1.2 ± 0.9 (range 1-5) distal anastomoses.  
428 patients (79.1%) received at least one new arterial graft. 
 
Statistical analysis 
 To test which variables were associated with increased perioperative risk and six-month 
mortality, a Fisher's exact test (univariant analysis) was used.  Multiple logistic regression  
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Table 2a.  Univariant analysis of preoperative variables.    
A: hospital mortality, B: early out-hospital mortality, C: early six-month mortality 
   Mortality 
  Patients N=541 
A 
N=36 (6.7) 
B 
N=39 (7.2) 
C = A + B 
N=75 (13.9) 
Variable Category N (%) N (%) p-value N (%) p-value N (%) p-value 
Age (years) <60  156 (31) 9  (5.5) 0.70 11 (6.7) 0.07 20 (12) 0.12 
 ³60 -<70  248 (46) 17 (6.9)  13 (5.2)  30 (12)  
 ³70 128 (24) 10 (7.8)  15 (12)  25 (20)  
Sex Female  107 (20) 8 (7.5) 0.67 11 (10) 0.21 19 (18) 0.21 
 Male  434 (80) 28 (6.5)  28 (6)  56 (13)  
Obesity No 407 (75) 24 (5.9) 0.23 29 (7.1) 0.85 53 (13) 0.32 
 Yes 134 (25) 12 (9.0)  10 (7.5)  22 (16)  
Diabetes No 445 (82) 31 (7.0) 0.66 18 (4.00 10-7 49 (11) 10-4 
 Yes 96 (18) 5 (5.2)  21 (22)  26 (27)  
Hipertens ión No 208 (38) 14 (6.7) 1.00 6 (2.9) 0.002 20 (9.6) 0.03 
 Yes 333 (62) 22 (6.6)  33 (9.9)  55 (17)  
Hyperlipidemia  No 224 (41) 12 (5.4) 0.38 17 (7.6) 0.87 29 (13) 0.71 
 Yes 317 (59) 24 (7.6)  22 (6.9)  46 (15)  
Vascular disease No 423 (78) 23 (5.4) 0.04 20 (4.7) 10-4 43 (10) 10-5 
 Yes 118 (22) 13 (11)  19 (16)  32 (27)  
Neurological dis. No 507 (94) 32 (6.3) 0.27 35 (6.9) 0.30 67 (13) 0.12 
 Yes 34 (6) 4 (12)  4 (12)  8 (24)  
Renal disease No 528 (98) 35 (6.6) 0.60 35 (6.6) 0.01 70 (13) 0.02 
 Yes 13 (2) 1 (7.7)  4 (31)  5 (39)  
Lung disease No 436 (81) 27 (6.2) 0.39 19 (4.4) 3.10-6 46 (11) 3.10-5 
 Yes 105 (19) 9 (8.6)  20 (19)  29 (28)  
PTCA No 466 (86) 34 (7.3) 0.21 34 (7.3) 1.00 68 (15) 0.28 
 Yes 75 (14) 2 (2.7)  5 (6.7)  7 (9.3)  
Pre-M.I. No 207 (38) 7 (3.4) 0.02 10 (4.8) 0.12 17 (8.2) 0.003 
 Yes 334 (62) 29 (8.7)  29 (8.7)  58 (17)  
Between M.I. No 397 (73) 16 (4.00 10-4 23 (5.8) 0.04 39 (9.8) 2.10-5 
 Yes 144 (27) 20 (14)  16 (11)  36 (25)  
Sinus rhythm No 32 (6) 4 (13) 0.16 5 (16) 0.07 9 (28) 0.03 
 Yes 509 (94) 32 (6.3)  34 *6.7)  66 (13)  
IMA-graft No 467 (86) 35 (7.5) 0.05 38 (8.1) 0.03 73 (16) 0.003 
 Yes 74 (14) 1 (1.4)  1 (1.4)  2 (2.7)  
Time period  ’87-‘92 230 (42) 24 (10) 0.003 15 (6.5) 0.62 39 (17) 0.08 
 ’92-‘98 311 (58) 12 (3.90  24 (7.7)  36 (12)  
PTCA: percutane transluminal coronary angioplasty, M.I.: myocardial infarction, IMA: internal 
mammary artery.  
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analysis was used to identify risk factors that independently predicted an increased or decreased 
risk of death.  A p-value of 0.05 or less was considered significant.  All mortality data are 
presented with 95% confidence interval (CI). 
 
Results 
 
 The overall risk for hospital, perioperative, and six-month mortality is 36/541 (6.7%, 
95% CI 4.6-6.8), 39/541 (7.2%, 95% CI 5.1-9.3), and 75/541 (13.9%, 95% CI 11.0-16.8 
respectively).  Cardiovascular causes were the reasons for mortality at six months in 64 patients 
(85%) [10]. 
 
Univariant analysis 
 The results of the univariant analysis are presented in Table 2 (a+ b). 
Risk factors for hospital mortality (A) include: peripheral vascular pathology (p = 0.04); 
myocardial infarction (p = 0.02); myocardial infarction between initial CABG and redoCABG (p 
= 10-4); No- IMA graft (p = 0.05); operative status (p = 0.003); perfusion time ³ 120 minutes (p 
= 0.001); antegrade delivery of cardioplegia (p = 0.008); perioperative myocardial infarction (p = 
7.10-6); and the earlier time period 1987 to 1992 (p = 0.003).   
 Risks for perioperative outpatient mortality (B) include: diabetes (p=10-7); hypertension 
(p = 0.002); peripheral vascular disease (p = 10=5); renal insufficiency (p = 0.01), pulmonary 
disease (p = 3.10-6); infarction between initial CABG and redoCABG (p = 0.04); No- IMA graft 
(p = 0.03); operative status (p = 10-7); mild valvular disease (p = 0.04); perfusion time ³ 120 
minutes (p = 0.04), and perioperative myocardial infarction (p = 2.10-8). 
 Risk factors for six-month mortality (C) include: diabetes (p = 10-4); hypertension (p = 
0.03); peripheral vascular disease (p = 10-5); renal insufficiency (p = 0.02); pulmonary disease (p 
= 3.10-5); myocardial infarction (p = 0.003); myocardial infarction between initial CABG and 
redoCABG (p = 2.10-5); cardiac rhythm other than sinus (p = 0.03); No-IMA graft (p = 0.003); 
operative status (p = 8.10-12); mild valvular heart disease (p = 0.02); perfusion time ³ 120 
minutes (p = 6.10-5); and perioperative myocardial infarction (p = 2.10-14). 
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Table 2b. Univariant analysis of perioperative variables  
A: hospital mortality, B: early out-hospital mortality, C: early six months mortality 
 
   Mortality 
  Patients N=541 
A 
N=36 (6.7) 
B 
N=39 (7.2) 
C=A+B 
N=75 (13.9) 
Variable Category N (%) N (%) p-value N (%) p-value N (%) p-value 
Operative 
status 
Elective 289 (53) 11 (3.8) 0.003 9 (3.1) 10-7 20 (6.9) 8.10-12 
 Acute 198 (37) 14 (7.1)  15 (7.6)  29 (15)  
 Emergency 54 (10) 11 (20)  15 (28)  26 (48)  
Mild valve 
disease 
No 495 (91) 31 (6.3) 0.22 32 (6.5) 0.04 63 (13) 0.02 
 Yes 46 (9) 5 (10.9)  7 (15)  12 (26)  
ECC-time 
(min) 
<120 212 (39) 5 (2.4) 0.001 9 (4.2) 0.04 14 (6.6) 6.10-5 
 ³120 329 (61) 31 (9.4)  30 (9.1)  61 (19)  
AoX-time 
(min) < 60 198 (37) 10 (5.1) 0.29 14 (7.1) 1.00 24 (12) 0.43 
 ³ 60 343 (63) 26 (7.6)  25 (7.3)  51 (15)  
Myocardial 
protection 
Retrograde 
 
305 (57) 12 (4.0) 0.008 23 (7.4) 0.87 35 (12) 0.08 
 Antegrade 230 (42) 23 (10)  16 (7.0)  39 (17)  
 Other* 6 (1) 1  0  1  
Perioperative 
MI 
No 452 (84) 20 (4.3) 7.10-6 19 (4.1) 2.10-8 39 (8.4) 2.10-14 
 Yes 89 (16) 16 (20)  20 (25)  36 (46)  
 
*Other  technique, not incorporated in the analysis concerning myocardial protection, because of the 
limited number of patients. 
ECC: extra corporal circulation, AoX; aortic cross clamp, MI: myocardial infarction 
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Multivariant analysis 
 Table 3 shows the results of the multiple logistic regression analysis. 
 
Table 3. Multivariant risk analysis  
A: hospital mortality, B: early out-hospital mortality, C: early six months mortality 
 Mortality 
 A N=36 (6.7) 
B 
N=39 (7.2) 
C=A+B 
N=75 (13.9) 
Preoperative variable  Odds Ratio p-value Odds Ratio p-value Odds Ratio p-value 
Age < 60 years 0.56 0.21 1.2 0.71 0.83 0.56 
Age > 69 years 1.56 0.34 2.0 0.13 2.0 0.05 
Sex (female/male) 0.90 0.81 0.27 0.62 0.72 0.34 
Obesity (yes/no) 1.8 0.14 0.83 0.67 1.3 0.38 
Diabetes (yes/no) 0.76 0.64 4.1 0.0005 2.5 0.008 
Hypertension (yes/no) 0.73 0.43 2.1 0.15 1.1 0.73 
Hyperlipidemia (yes/no) 1.6 0.24 1.1 0.85 1.3 0.33 
Vascular disease(yes/no) 1.9 0.13 1.8 0.15 2.1 0.02 
Neurological disease (yes/no) 1.4 0.60 1.0 0.99 1.2 0.68 
Renal disease (yes/no) 2.1 0.51 1.9 0.47 2.8 0.17 
Lung disease (yes/no) 1.4 0.49 2.6 0.02 2.0 0.02 
PTCA (yes/no) 0.45 0.31 1.4 0.57 0.86 0.75 
Previous M.I. (yes/no) 1.2 0.70 1.5 0.41 1.3 0.45 
Between M.I. (yes/no) 4.0 0.003 1.5 0.39 3.0 0.002 
Sinus rhythm (yes/no) 0.79 0.72 1.1 0.84 1.0 0.95 
Patent-IMA-graft (yes/no) 0.40 0.39 0.15 0.07 0.21 0.04 
Time period ’87-’92 /’93-‘98 0.26 0.002 0.90 0.81 0.43 0.007 
       
Perioperative variable        
Acute operation (versus elective) 2.6 0.06 1.7 0.28 2.2 0.05 
Emergency operation  (versus 
elective) 11.1 10
-4 7.5 0.001 14.9 10-4 
Mild valve disease (yes/no) 1.3 0.70 0.90 0.88 1.2 0.77 
Perfusion time (< 120 / ³120) 3.7 0.03 1.7 0.34 3.2 0.007 
AoX time (<60 / ³60) 0.88 0.79 0.41 0.09 0.48 0.07 
Myocardial protection 
(retro/ante) 2.6 0.08 0.90 0.83 1.6 0.25 
Perioperative M.I. (yes/no) 4.1  0.003 8.1 10-4 10.3 10-4 
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For hospital mortality (A) a myocardial infarction (p = 0.003), the time period of surgery 
1987 to 1992 (p = 0.002), emergency operation (p = 10-4), perfusion time ³ 120 minutes (p = 
0.03), a perioperative myocardial infarction (p = 0.003) are all identified as independent 
variables predicting hospital death.  For patients, their outpatient perioperative mortality (B) 
was predicted by diabetes (p = 0.0005), pulmonary disease (p = 0.02), emergency operation (p 
= 0.001), and perioperative myocardial infarction (p = 10-4). 
 Predictors for six-month mortality (C) include: age > 69 years (p = 0.05); diabetes 
mellitus (p = 0.008); peripheral vascular disease (p = 0.02); pulmonary disease (p = 0.02); 
myocardial infarction between initial CABG and redoCABG (p = 0.002); occluded IMA graft 
(p = 0.04); and also the time period of surgery 1987 to 1992 (p = 0.007).  Independent 
perioperative variables include: acute operation (p = 0.05); emergency operation (p = 10-4), 
perfusion time ³ 120 minutes (p = 0.007); and perioperative myocardial infarction (p = 10-4). 
 
Comment 
 
 Redo coronary bypass surgery is known to be high-risk surgery.  High mortality and 
morbidity rates are described in several reports [1-8].  This study is focused on mortality 
within the first six months following operation.  The choice for this time interval is based on 
the work of Blackstone [9], who describes a prolonged early phase in high-risk patients.  
Several clinical studies have also highlighted the importance of analysis of this period 
[11,12].  Hospital mortality is defined as any death occurring during their hospitalization at 
the UMC St. Radboud where the patient underwent redoCABG.  Thus hospital mortality 
included not only surgical deaths, but also patients who died after a complicated postoperative 
recovery.  All hospital deaths are included.  The perioperative outpatient mortality is the 
period between hospitalization and six months.  This includes all patients who died after 
discharge from the UMC St. Radboud.  All of these patients were in good condition at the 
time of discharge from the UMC St. Radboud.  An event then occurred within the first six 
months after their redoCABG that lead to their death.  It is important to note that none of 
these patients died after transfer to their referring cardiac center, which would have to have 
been considered as part of their hospitalization.  A number of variables were selected for 
study, but the list was not all- inclusive.  Certain variables such as left ventricular function, 
identified as a predictor for hospital and late mortality in several reports [1,3,4] were not 
included because the data was not available in our database.  Ejection fraction is not routinely 
calculated for all patients, except for those with severe decrease in their left ventricular 
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function.  Seven patients had a documented ejection fraction lower than 30%.  Because of the 
limited number of patients with documented, impaired left ventricular function, we excluded 
this variable in our analysis.  Myocardial infarction may influence left ventricular function 
and survival, thus infarction before the initial CABG and infarction occurring between the 
initial procedure and the reoperation are included.  The presence of a patent IMA graft is 
included in our analysis; however, the patency and the degree of disease in old vein grafts is 
not.  Perioperative variables such as lack of graft material and completeness of 
revascularization during redoCABG are also not included in this analysis. 
 Over the study period, the percentage of redoCABG's increased from 10% in 1987 to 
12% in 1998.  In this study, only patients who had isolated myocardial revascularization at 
both operations were included.  Our hospital mortality of 6.7% and six-month mortality of 
13.9% is comparable with other reports [1-6].  The finding of an additional 7.2% 
perioperative outpatient mortality is alarming and confirms again the importance of a longer 
follow-up period for the evaluation of early mortality in high-risk patients [9, 11, 12].  Simply 
looking at hospital mortality may not give an accurate picture as to a patient's true risk after a 
complicated procedure. 
 Looking at the univariant analysis of these patients, we have found that their hospital 
mortality is influenced by the presence of peripheral vascular disease, myocardial infarction 
between the initial operation and redo, and occluded IMA grafts, operative status (emergency 
vs. elective), ECC time ³ 120 minutes, antegrade delivery of cardioplegia, occurrence of 
perioperative myocardial infarction, and also the time period of their surgery 1987 to 1992. 
 Several factors also help define the mortality at 6 months.  The presence of diabetes, 
hypertension, peripheral vascular disease, renal insufficiency, pulmonary disease; myocardial 
infarction between operations, lack of sinus rhythm, No-IMA grafts, operative status 
(emergency vs. elective), mild valvular disease, time on cardiopulmonary bypass, 
perioperative myocardial infarction, and the time period 1987 to 1992 all were associated with 
increased mortality. 
 Most of these same variables have been identified as risk factors for mortality in 
previous reports [1-6].  In these reports, however, there are different definitions of mortality 
as it relates to the procedure.  With our distinction between hospital and six-month mortality, 
we see the importance of different risk factors during the first six months.  By looking at 
perioperative mortality, we have been able to look at three distinct time periods within the 
first six months.  The importance of the identified risk factors is demonstrated in Table 4  
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Table 4. Risk factors related to mortality , (univariant and multivariant analysis) after first 
redo-coronary artery bypass, and the phase in which they exert their effect. 
Risk factor Mortality 
 A Hospital 
B 
Early out-hospital 
C = A+B 
Early six-month 
UNIVARIANT ANALYSIS 
 Diabetes  + + 
 Hypertension  + + 
 Vascular disease + + + 
 Renal disease  + + 
 Lung disease  + + 
 Pre-MI +  + 
 Between MI + + + 
 No sinus rhythm   + 
 No-patent-IMA-graft + + + 
 Acute-emergency + + + 
 Valve disease  + + 
 ECC-time  + + + 
 Antegrade Cardioplegia  +   
 Perioperative myocardial 
infarction + + + 
 Time period  ’87-‘92 +   
MULTIVARIANT ANALYSIS 
 Age > 69 years   + 
 Diabetes  + + 
 Vascular disease   + 
 Lung disease  + + 
 Between MI +  + 
 No-IMA-graft   + 
 Acute operation    + 
 Emergency operation + + + 
 ECC time  +  + 
 Perioperative MI + + + 
 Time period ’87-‘92 +  + 
ECC=extracoporal circulation; IMA= internal mammary artery; MI=myocardial infarction. 
 
Vascular disease, as a mirror of the extent of atherosclerosis for the patient, myocardial 
infarction and subsequent myocardial infarction after the first CABG, as well as the influence 
of ventricular function, are all important predictors of hospital mortality.  The presence of a 
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patent IMA graft has been shown to decrease the mortality and morbidity of redo surgery [8, 
13, 14].  The importance of a patent IMA graft is further illustrated by reports tha t show that 
an injury to a patent IMA graft increases mortality [13].  The importance of retrograde 
cardioplegia is well known [6], and it seems logical that the influence of operative myocardial 
protection is reflected in the hospital mortality.  The effect of a prolonged period of 
cardiopulmonary bypass (³ 120 minutes) may be relative; a technically difficult operation 
often leads to a longer pump time.  Patients with difficulty in coming off of bypass may also 
have a longer pump time.  Thus, the influence of prolonged extracorporeal circulation time 
may be related to other factors that increase extracorporeal circulation time and not the time 
per se.  The fact that patients operated on before 1992 had an increased risk is likely due to 
improved myocardial protection and retrograde cardioplegia, as well as more experience with 
redo operations by our group.  The influence of an emergency operation, and the presence of a 
perioperative myocardial infarction are both important risks, and have been confirmed by 
several others [1-7].  This report, however, also demonstrates that the influence is not only on 
hospital mortality, but also for the early six-month mortality (emergency/acute operations, 
perioperative myocardial infarction) and is balanced over the whole first six months (early 
post-discharge mortality for emergency procedures and perioperative myocardial infarction).  
In coronary artery bypass graft surgery, unstable angina is an incremental risk factor for death 
during the early hazard phase [11].  No-IMA grafts have a balanced influence, however, of 
lesser importance.  The influence of initial myocardial infarction and perioperative 
myocardial infarction between operations, cardiopulmonary bypass time (³ 120 minutes, on 
the six-month mortality seems to be a consequence of their importance on the hospital 
mortality.  On the other hand, the influence of vascular disease, mild valvular heart disease, 
on the six-month mortality is related to the early perioperative mortality.  Diabetes, 
hypertension, renal insufficiency, and pulmonary disease are indicated as risk factors for six-
month mortality, but their influence is mainly in the early discharge perioperative mortality.  
The way of delivery of cardioplegia, and the time the operation was performed does not seem 
to be related to the six-month mortality.  The absence of sinus rhythm, however, is a 
significant risk factor for the six-month mortality, but not for the hospital mortality, and for 
early discharge perioperative mortality; however, there is a trend toward significance.  The 
limited number of patients without sinus rhythm undergoing a redo operation (6%) is 
probably a reason that significance is not reached in the outpatient perioperative mortality. 
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Multivariant analysis 
 Multivariant analysis identified age > 69 years, diabetes, peripheral vascular disease, 
pulmonary disease, myocardial infarction between operations, No-IMA grafts, time period 
1987 to 1992, emergency operations, cardiopulmonary bypass time ³ 120 minutes, and 
perioperative myocardial infarction as independent risk factors for early six-month mortality.  
As in the univariant analysis, there are differences in these factors during the first six months 
following surgery (Tables 2 and 3).  Age > 69 years, peripheral vascular disease, No-IMA 
grafts, and emergency surgery were all significant predictors for six-month mortality, with a 
spread risk over the whole time period.  Diabetes and pulmonary disease, however, were 
important in the early outpatient perioperative period, and did not appear to influence 
mortality in the immediate postoperative period.  Acute myocardial infarction between 
operations, the time period 1987 to 1992, and the ECC time influenced the inpatient mortality.  
The same factors that may have affected the prolonged extracorporeal circulation time that 
were discussed in the univariant analysis also apply to the multivariant analysis as well.  
Emergency operations and a perioperative myocardial infarction are, however, the strongest 
independent risk factors for early mortality for both the hospital and the outpatient 
perioperative mortality.  It seems strange that the way of delivery of cardioplegia is not 
identified as an independent predictor of hospital mortality.  This is of interest because of the 
time period 1987 to 1992 was significant.  The use of retrograde cardioplegia has increased 
since 1992 and since 1993, cardioplegia is delivered in a retrograde fashion predominantly.  
Since the time period 1987 to 1992 appears to be an independent predictor for early six-month 
mortality, especially for hospital mortality, means that factors not incorporated in this risk 
analysis, related to the time cohort, are important.  Growing surgical experiences in period 
1993 to 1998 may be part of the explanation.  Most of the redoCABG's were performed by 
one surgeon (LN), the changing profile of the patient population [15], and completeness of 
revascularization  are all possible variables.  Another possibility is that retrograde delivery of 
cardioplegia alters the occurrence of a perioperative myocardial infarction, which is an 
independent predictor of hospital outpatient perioperative and six-month mortality.  Renal 
disease, identified in several reports as an independent predictor [4, 5], was not identified as 
an independent risk factor in our analysis.  However, renal disease has an odds ratio of 2.8 for 
early mortality, indicating a higher risk for these patients.  That we did not reach statistical 
significance is probably related to the limited number of patients with renal disease (6.6%) in 
our series. 
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 The aim of this study was to identify risk factors for early six-month mortality.  
Therefore, statistical analysis in this study is limited to a univariant and multivariant analysis.  
The finding that different variables, or the same variables, have a different importance at 
different times as a risk factor for early six-month mortality is the conclusion of the study.  At 
the same time there is also the confirmation of the mortality rates when the early outpatient 
perioperative mortality is superimposed on the hospital mortality.  This fact may be helpful in 
counselling surgeons and patients about the true risk of redo coronary bypass surgery, and 
eventually allow the construction of models that may allow for a reduction of mortality.  
These models, however, would be limited to preoperative variables and will not likely include 
perioperative ones, such as cardiopulmonary bypass times, or completeness of 
revascularization during the reoperations [10].   
  
In conclusion, the present study emphasizes that early mortality after a redo coronary 
artery surgery is influenced by several variables at different times.  Insight into this time-
related influence of variables associated with an increased risk may explain the different 
results of risk analysis in several reports and help point out factors that contribute to death 
soon after surgery, and death that occurs after hospital discharge.  Emergency operation and 
the occurrence of a perioperative myocardial infarction, however, are the crucial independent 
risk factors for early mortality after redo surgery. 
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Abstract 
 
Objective: Construct a predictive model for early mortality in coronary reoperations 
(RECABG). 
Methods: Five hundred and forty one RECABG (1987-1998) were studied by univariate and 
multivariate analysis. Stepwise selective procedure ( p<0.05) was used to identify a subset of 
variables with prognostic value for early mortality. This subset was used to calculate a 
prognostic  score ‘S’ and a predicted probability ‘P’ for early mortality, P= 1/ 1+e-S . 
Sensitivity analysis was used for evaluation.  
Results: The best predictive variables for early mortality were diabetes, vascular-, lung-
disease, a myocardial infarction between the primary and the RECABG, acute- and 
emergency operation, and the operative period. The prognostic accuracy (ROC area) was 
80%.  Observed probabilities compare well with the predicted probabilities, and patients were 
classified in low risk (5%), intermediate risk (15%), high risk (30%) and very high risk 
(40%). A predicted probability of  ³ 0.40 was used as cut-off point for the prognostic test. The 
specificity of this test was 97%, sensitivity 33%, predictive value of a positive test 63%, and 
90% for a negative test.  
Conclusion: The results show that individual patients presented for RECABG, can be 
stratified according to their early mortality risk. This information can be used, to inform the 
patient, but also to discus the opportunity of the RECABG.  
 
Key words   
Reoperation, Early mortality, Prediction, Myocardial revascularization
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1. Introduction 
 
Mortality of coronary reoperations (RECABG) is still higher than in primary 
myocardial revascularization [1-6]. As in all surgical procedures, to improve the results, 
progress has to be made in the preoperative, perioperative and postoperative phase.  A better, 
evidence based, patient selection can be a first step in the improvement of the results of 
RECABG.  The intention of this study is to construct a predictive model of early mortality of 
RECABG, using preoperative variables.  In the study, early mortality is the end-point. Early 
mortality, 6 months postoperative, is related to patient-variables and the surgical procedure 
[7], and is therefore a more honourable endpoint than surgical-, hospital-  or 30-day-mortality, 
which are used as endpoint in most other reports.    
 
2. Material and Methods  
2.1 Patients 
With the aid of our database, Coronary Surgery Database Radboud Hospital 
(CORRAD), a registry that stores pre-, peri-, postoperative and follow-up data on all patients 
undergoing isolated coronary bypass grafting, we identified a series of 541 patients 
undergoing a first coronary reoperation (RECABG) from January 1987 to December 1998 at 
the UMC St.Radboud Nijmegen. Only patients with an isolated myocardial revascularization 
at the primary operation were included in this study.  
The studied variables and their definition are presented in table 1.  
 
2.2 Surgical technique 
Our surgical technique is described in previous papers [5,6]. The mean bypass time 
was 140 ± 60.8 minutes (range 25-485), and the mean duration of aortic cross-clamping was 
70 ± 33.6 minutes (range 10-227). There was a mean of 2.4 ± 0.8 grafts (range 1-5), and a 
mean of 3.2 ± 1.2 (range 1-7) distal  anastomoses. Of the used grafts 1.0 ± 0.6 (range 1-2) 
were arterial grafts with 1.2 ± 0.9 (range 1-5) distal anastomoses and 428 patients (79.1 %) 
received at least one new arterial graft.  
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Table 1. Unifactor risk analysis for early mortality  
Variable                                                                                                         [number of patients][%] Number (%) p-value 
Age (years) mean age: 63.7 ±13.5 (range: 31-91)                                0.12 
   Age < 60                                                                                                                            [165] [31] 20 (12)  
   60 ³ age <70                                                                                                                      [248] [46] 30 (12)  
   Age ³ 70 years                                                                                                                   [128] [24] 25 (20)  
Sex  0.21 
   Female                                                                                                                                [107] [20] 19 (18)  
   Male                                                                                                                                   [434] [80] 56 (13)  
Obesity: Body Surface Area (BSA) > 2.1                                                                            [134] [25]  22(16) 0.32 
Diabetes:  Diet-controlled, oral therapy or insulin dependent diabetes                                 [96] [18] 26 (27) 10-4 
Hypertension:  Systolic blood pressure > 160 mmHg, or diastolic pressure > 100 mmHg. Or 
antihypertensive medication.                                                                                                [333] [62] 
55 (17) 0.03 
Hyperlipidemi a:  Total cholesterol > 250mg/dl /triglyceride> 200 mg/dl                         [317] [59] 46 (15) 0.71 
Vascular disease:  Peripheral -, abdominal vascular pathology or operation                     [118] [22]   32 (27) 10-5 
Neurological disease:  Cerebrovascular accidents and /or transient ischemic attack             [34] [6] 8 (24) 0.12 
Renal disease: creatinine ³ 150 mmol /L, preoperative dialysis, renal transplantation          [13] [2]   5 (39) 0.02 
Lung disease: Chronic obstructive pulmonary dis ease / history of previous lung disease [105] [19] 29 (28) 3.10-5 
PTCA:  History of previous percutaneous transluminal coronary angioplasty                     [75] [14] 7 (9.3) 0.28 
Pre-Myocardial infarction (M.I.): History of MI before the first operation                     [334] [62]   58 (17) 0.003 
Between- M.I.: History of M.I. between the first operation and the reoperation.               [144] [27]  36 (25) 2.10-5 
Rhythm:     No-preoperative sinus rhythm                                                                              [32] [6] 9 (28) 0.03 
Internal mammary artery graft (IMA-graft):   No-patent IMA graft at the reoperation [467] [86]       73 (16) 0.003 
Operative status  8.10-12 
  Elective:                                                                                                                             [289] [53] 
Stable cardiac function, usually scheduled at least one day prior to the surgical procedure.   
20 (6.9)  
  Urgent:                                                                                                                               [198] [37] 
surgery is required within 24 hours after admission 
29 (15)  
  Emergency:                                                                                                                          [54] [10] 
evolving infarction, ischemia not responding to medical therapy, or cardiogenic shock. 
26 (48)  
Operative period:  0.08 
  ’87- ’92                                                                                                                               [230] [43] 39 (17)  
  ’93- ’98                                                                                                                               [311] [58] 36 (12)  
 
2.3 Statistical analysis 
To test which variables can be considered risk factors for early mortality, Fisher’s 
exact test  (unifactor analysis) was used. Multiple logistic regression analysis was used to  
identify risk factors that independently contributed to increased or decreased risk. The odds 
ratio’s derived from the parameter estimates in the logistic regression analysis can be 
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considered estimates of relative mortality risk. To identify a subset of variables with   
prognostic value for early mortality a stepwise selective procedure was used at a significance 
level  p £  0.05 (significant level for entry respectively stay into the prognostic model). A 
receiver operating characteristics curve (ROC) was calculated to measure the prognostic value 
of this subset.  This subset was then used to calculated a prognostic score ‘S’ and a predicted 
probability ‘P‘ for early mortality.  The prognostic score ‘S’ is a linear function of the 
variables included in the selected subset. If the variables are selected the ‘S’-score is 
represented by S=b0+b1X1+b2x2+….. bhxh. The predicted probability (P) for early mortality 
is calculated by P= 1/1+e-s.   Sensitivity analysis, ( 2´ 2 table)  was used for evaluating the 
effect of the initial estimate on the final decision.  
 
3. Results 
 
The a priori (average) risk for early mortality is 75/541 (13.9%). Myocardial infarction 
was the direct cause of death in 25 patients, and in five patients the cause of death was not 
clear (Table2).  
 
Table 2. Causes of  75 early deaths . 
Cause N = 75 % 
Myocardial infarction 25 33 
Low cardiac output 21 28 
Arrhythmia  10 14 
Respiratory 3 4 
Sepsis 3 4 
Stroke 4 5 
Heart failure 4 5 
Unknown 5 7 
 
Results of the unifactor risk analysis are presented in table 1. Risk factors for early mortality 
are: diabetes (p=10-4), hypertension (p=0.03), vascular disease (p=10-5), renal disease 
(p=0.02), lung disease (p=3.10-5), pre-myocardial infarction ( p=0.003), between-myocardial 
infarction ( p=2.10-5), no-sinus rhythm (p=0.03), no patent IMA graft ( p=0.003) and No-
elective operation ( p=8.10-12). If the latter risk factor is present then the risk of early 
mortality amount to 48 %. Multifactor risk analysis (table 3) Identified the operative period, 
diabetes, lung disease, between-myocardial infarction, acute-, and emergency operation, as  
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Table 3. Multifactor risk analysis, logistic regression analysis, for early mortality  
 N=75 (13.9)  
Preoperative variable  Odds Ratio P-value 
Age < 60 years 0.87 0.69 
Age > 69 years 1.6 0.22 
Sex (female/male) 0.76 0.44 
Obesity (yes/no) 1.1 0.83 
Diabetes (yes/no) 2.5 0.01 
Hypertension (yes/no) 0.8 0.51 
Hyperlipidemia (yes/no) 1.2 0.47 
Vascular disease(yes/no) 1.7 0.11 
Neurological disease (yes/no) 1.8 0.24 
Renal disease (yes/no) 2.6 0.22 
Lung disease (yes/no) 1.9 0.05 
PTCA (yes/no) 0.70 0.47 
Previous M.I. (yes/no) 1.3 0.44 
Between M.I. (yes/no) 2.6 0.009 
Sinus rhythm (yes/no) 1.0 0.99 
Patent-IMA-graft (yes/no) 0.31 0.13 
Acute operation (versus elective) 2.0 0.05 
Emergency operation  (versus elective) 10.9 1.10-4 
Time period ’87-’92 /’93-‘98 0.31 5.10-4 
 
independent risk factors for early mortality. The odds ratio’s (estimates of relative risk) are 
respectively: 0.31,2.5, 1.9, 2.6, 2.0 and 10.9.  
Using stepwise logistic regression analysis, the following variables were selected for  
prediction of early mortality: operative period, diabetes, vascular-, lung-disease, between 
myocardial infarction, acute and emergency operation. The associated regression coefficients 
(bi), odds ratio’s, and p-values are presented in table 4.  
 
Table 4. Stepwise logistic regression analysis. Variables selected for prediction of early 
mortality.  
Preoperative variable  Regression bi 
coefficient (±SE) 
Odds Ratio P-value 
Intercept -2.89 (0.29)   
Diabetes (yes/no) 0.88 (0.34) 2.4 0.009 
Vascular disease(yes/no) 0.69 (0.320 2.0 0.03 
Lung disease (yes/no) 0.68 (0.32) 2.0 0.03 
Between M.I. (yes/no) 1.07 (0.30) 2.9 3.10-4 
Acute operation (versus elective) 0.69 (0.33) 2.0 0.03 
Emergency operation  (versus elective) 2.46 (0.41) 11.7 1.10-4 
Time period ’87-’92 /’93-‘98 -1.17 (0.31) 0.31 1.10-4 
 Note: area under the ROC =0.80.  
The ROC curve gave an area under the curve value of 0.80.  
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The S –score for an individual patient is calculated as follows:  S= - 2.89 - 1.17 (time 
period) + 0.88 (diabetes) + 0.69 (vascular disease) + 0.68 (lung disease) + 1.07 (between 
myocardial infarction) +0.69 (acute operation) + 2.46 (emergency operation) 
 
Table 5. Distribution of the S-scores in group of patients with (n=75) and without (n=466) early 
mortality  (s-score classified into discrete classes). 
    S-score     
Group -4 -3 -2 -1 0 1 2  
No early mortality 7 (16) 171 (37) 162 (35) 37 (8) 19 (4) 3 (0.6) 0 (0) 466 
Early mortality 1 (1) 13 (17) 16 (21) 13 (7) 18 (24) 9 (12) 5 (7) 75 
Note: score –2 means (-2.5) – (-1.5) 
 
Table 6. Distribution of predicted probabilities ( P) in group of patients with (n=75) and without 
(n=466) early mortality. Classes defined as: 0 = 0£P<0.10; 1= 0.10£P<0.20; … 8=0.80£P<0.90 
 Predicted probability  
 0 1 2 3 4 5 6 7 8  
No early mortality 
(%) of the total (n=466) 
294 
(63) 
115 
(25) 
25  
(5) 
17  
(4) 
4 
(0.9) 
7 
(1.5) 
3 
(0.6) 
1 
(0.2) 
0 466 
Early mortality 
(%) of the total (n=75) 
15 
(20) 
16 
(21) 
8  
(11) 
11 
(15) 
3  
(4) 
7  
(9) 
4  
(5) 
6  
(8) 
5  
(7) 
75 
Observed mortality  (%) 4.9 12 24 39 43 50 57 86 100  
 
The distribution of the S-scores and predicted probabilities P for early mortality in the  
group with  (n=75) and without  (n=466) early mortality is presented in table 5 and 6.  
The Scores are classified into the following classes: -4 (-4.5) – (-3.5); -3: (-3.5) – (-2.50) …. 
2: (1,5) – (2.5). For the probability, following classification is used: 0:  0£ P< 0.10; 1: 
0.10£P<0.20; … :0.80£P<0.90. The observed probabilities in these discrete classes compare 
well with the mid-points of the predicted probabilities (table 5b) (note the number of patients 
in the classes 4,5,6,7, 8 are very low).  
We decide to classify patients in low risk, intermediate risk, high risk and very high 
risk patients (table 7). The a priori average risk of early mortality is 75/541 (14%). Using the 
S-score and the predicted probability P, we classify patients in low risk  (5%), intermediate 
risk  (15%), high risk (30 %), and very high risk (40%). The observed mortality in these risk 
groups compare well with the predicted (4.9%, 12%, 31%, 63%).   
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Table 7. Classification of patients in low risk, intermediate risk, high risk and very high risk 
patients. 
 Risk category  
 Low Intermediate High Very high  
Predicted probability 5% 15% 30% ³ 40%  
Class 0£P<0.10 0.10£P<0.20 0.20£P<0.40 p³0.40  
No early mortality 294 115 42 15 466 
Early mortality 15 16 19 25 75 
TOTAL (%) 309 (4.9) 131 (12) 61 (31) 40 (63) 541 (14) 
 
We use a predicted probability P³0.40 (risk category very high ) as a cut-off point for 
constructing a prognostic test for early mortality. The specificity of the test is high (0.97), but 
a low sensitivity  (0.33). The predictive value of a positive respectively negative test are 
respectively 0.63 and 0.90 (Table 8).     
 
Table 8. 2x2 table for the evaluation of the early mortality prediction 
 
4. Discussion 
 
 The intention of this study is to construct a predictive test to evaluate preoperatively 
the risk for early mortality of a patient presented for RECABG.  A better selection of patients 
undergoing RECABG is a first step in order to minimize mortality and morbidity. We 
focussed our study on early mortality because this 6-months-mortality is related to patient 
variables and therefore a honourable endpoint to do a prediction of mortality risk of the 
 Prognostic test  
Early Mortality T=0 
P< 0.40 
T=1 
P³ 0.40 
 
No (D=0) 451 15 466 
Yes (D=1) 50 25 75 
 501 40 541 
    
Sensitivity : P[T=1/D=1] = 25/75 = 0.33  
Specificity: P[T=0/ D=0] = 451/466 = 0.99  
Predictive value of positive test: P[D=1/T=1] = 25/40 = 0.63 
Predictive value of negative test: P[D=0/T=0} = 451/501 = 0.90 
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operation  [7]. In our previous study we analysed risk factors of early mortality in RECABG, 
and concluded that several pre-and peroperative variables were independent predictor of early 
mortality, with their there influence on different moments [8]. However in the present study 
we included only preoperative variables in the analysis, because we want to evaluate and 
inform the patient preoperatively about his risk.  
 Cardiovascular causes were the reason of early mortality in 64 patients. In five patients 
we could not verify the cause of death, cardiac or not cardiac related, these patients were 
noted as unknown cause of mortality.  
Using stepwise logistic regression analysis, the operative period, diabetes, vascular-  
and lung disease, between myocardial infarction, acute and emergency operation were 
identified as predictive for early mortality. Independently of forwards or backwards 
performed regression analysis these variables were selected. These variables were comparable 
with variables selected in other studies [1,3,4]. The positive influence of the time period ’93-
’98 can be related to several factors, growing surgical experiences in redosurgery, changing 
profile of the patients, as discussed in our previous report [6].  The area under the ROC curve 
(0.80) indicates that good discrimination remains between yes or no early mortality.  
  By using these seven variables we created a risk score. We classified patients in low 
risk (5%), intermediate risk (15%), high risk (30%) and very high risk (40%) for early 
mortality. The observed mortality in these risk groups compare well with the predicted (table 
7). The specificity of our test is high, as required for a prognostic test, but we have a low 
sensitivity. Still the test is useful to select patients with a very high risk on mortality. The 
predictive value of a positive respectively negative test are 0.63 and 0.90 (table 8) 
respectively. This means that if the test is negative, there is only 10% risk on early mortality 
on the other hand, if the test is positive, there is 63% risk that the patient will die during the 
first six months.   
 As for all other prediction-models [9,10], it must be clear, that such a model never 
predict the specific outcome of an individual patient. Each patient will die or survive. 
However, with a predictive model we can inform ourselves and the patients about the 
probability of the risk of mortality.  
However, even more than in primary myocardial revascularization, the outcome in 
RECABG, is also related to perioperative variables. The importance of operative status and 
perioperative myocardial infraction as independent variables for mortality is documented in 
almost all studies concerning RECABG [1-6]. We included operative status as a preoperative 
variable in our predictive model, however, it is impossible to include a perioperative 
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myocardial infarction as a preoperative variable in the predictive model. A perioperative 
myocardial infarction is related to several preoperative variables, such as diseased vein grafts, 
the native coronary system but also to a lot of operative variables. Route of delivery of 
cardioplegia, completeness of the revascualization, peroperative spreading of debris from vein 
grafts in distal coronary arteries, are operative variables related to the occurrence of a 
perioperative myocardial infarction. The impact of a perioperative myocardial infarction on 
the early mortality is however, important [1-4]. We must therefore realise that our prediction 
of likely risk of early mortality after RECABG, flatters the reality if a patient has a 
perioperative myocardial infarction. Furthermore this is a single institution experience, and 
several variables are not incorporated in the analysis. Ejection fraction, is not calculated for 
all patients, and therefore not incorporated in the analysis. However, by using the variables 
myocardial infarction and between infarction we try to have an idea about ventricular 
function. Other variables as lack of graft material, a calcified aorta, previous mediastinitis, are 
certainly variables increasing the operative risk  
 On the other hand, with our predictive model, we have an evidence-based instrument 
to identify preoperatively high risk patients for RECABG. This can influence our strategy on 
several points, the decision to operate or not, operative strategy, type of anaesthesia, 
postoperative care.  
  
In conclusion; with our predictive model we can stratify patients presented for 
RECABG, according to their risk for early mortality. Based on this stratification we can not 
only inform the patient concerning the risk, but also discus the opportunity of the RECABG. 
At this point we can improve our results by making a better preoperative patient selection.       
 
 
 We thank Johannes M van Druten, PhD, department of Medical Informatics, Epidemiology and Statistics, 
University of Nijmegen, for the statistical analysis.  
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Appendix A. Example of  the predictive model 
 
Formula 
Calculation for the S-Score:  
S= -2.89 – 1.17 ( time period) + 0.88 ( diabetes) + 0.69 ( vascular disease) + 0.68 (lung  
disease)  + 1.07 (between infarction) + 0.69 ( acute operation) + 2.46 ( emergency 
operation)   
Calculation of the predicted probability:  
P=1/1+e-S 
 
Case 
Patient: 73 years old male, insulin dependent diabetes, history  of vascular disease, no lung 
disease, history of a myocardial infarction after the first operation.  
First calculation if this patient is presented for an elective operation 
Second calculation if this patient is presented is presented for an emergency operation 
 
Elective operation:  
S= -2.89 – 1.17 (1) + 0.88 (1) + 0.69 (1) + 0.68 (0) + 1.07 (1) + 0.69 (0) + 2.46 (0) = -1.42   
P=1/1+e-(-1.42) = 1/1+4.13 = 0.19 
Classification: intermediate risk category ( 0.10 £P <0.20), predicted probabilty 15% 
 
Emergency operation:  
S= -2.89 – 1.17 (1) + 0.88 (1) + 0.69 (1) + 0.68 (0) + 1.07 (1) + 0.69 (0) + 2.46 (1) = 1.04   
P=1/1+e-(1,04) = 1/1+ 2.8 =0.73 
Classification: Very high  risk category (P >0.40), predicted probalility ³ 40% 
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Abstract:  
 
Objective: Analyse risk factors and construct a predictive model for identification of risk 
patients for early out-of-hospital mortality after coronary reoperations(RECABG). 
Methods: 505 patients, discharged from hospital after a RECABG (1987-1998) were studied 
by uni- and multivariate analysis.  A Stepwise selective procedure (P<0.05) was used to 
identify a subset of variables with prognostic value for early out-of-hospital mortality. This 
subset was used to calculate a prognostic score ‘S’ and a predicted probability ‘P’ for early 
out-of-hospital mortality, P= 1/1+ e-S . Sensitivity analysis was used for evaluation.  
Results: The best predictive variables for early out-of-hospital mortality were diabetes (P= 
0.002), lung disease (P=0.05), emergency operation (P= 0.0001) and a perioperative 
myocardial infarction (P=0.0001).   Emergency operation (P=0.001) and ante/retrograde 
cardioplegia ( P<0.0000) were independent predictors of a perioperative myocardial 
infarction. The prognostic accuracy (ROC area) was 86%.  Patients were classified in low risk 
(5%), intermediate risk (15%), high risk (30%) and very high risk  ( ³ 40%).  A predicted 
probability of ³ 0. 40  was used as cut-of point. The specificity of this test was 99%, 
sensitivity 33%, predictive value of a positive test 79%, and 95% for a negative test. 
Conclusion: The results show that patients discharged from hospital after RECABG, can be 
stratified according to their early out-of-hospital risk.  A perioperative myocardial infarction 
is the major independent risk factor and can be affected by use of retrograde cardioplegia.  
 
Key words  
Coronary reoperation, mortality, out of hospital, prediction 
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1. Introduction 
 
Mortality of coronary reoperations (RECABG) is still higher than in primary 
myocardial revascularization.1-6 In our previous study we demonstrated that early mortality, 
six months postoperative, after redosurgery is influenced by several variables at different 
times.7 Based on this time-related insight we constructed a predictive model for this early 
mortality, on preoperative variables.8 The intention of this study, however, is to analyse and 
predict the early ‘out-of-hospital‘ mortality, defined as mortality within the first six months 
postoperatively after discharge from the hospital. Because prediction of out-of-hospital 
mortality is only meaningful for patients surviving the operation, we use the term 
postoperative prediction.   It must be clear that this study is complementary with our previous 
report,8 but different because this study analyse early mortality of the patients surviving the 
RECABG.   
  
2. Material and Methods  
2.1 Patients 
With the aid of our database, Coronary Surgery Database Radboud Hospital 
(CORRAD), a registry that stores pre-, peri-, postoperative and follow-up data on all patients 
undergoing isolated coronary bypass grafting, we identified a series of 505 patients 
discharged from UMC St Radboud Nijmegen hospital after a first coronary reoperation 
(RECABG) from January 1987 to December 1998. Only patients with an isolated myocardial 
revascularization at the primary operation and at the RECABG were included in this study.  
During this period, 541 patients underwent a RECABG at the UMC St. Radboud Nijmegen 
hospital.7 Our hospital mortality, including operative mortality and mortality at the university 
hospital during hospital stay at the UMC St. Radboud after the RECABG, is 36/541 (6.7%, 
95% CI 4.6-8.8). The early out-of-hospital mortality, is defined as al cardiac mortality in the 
first six postoperative months but after discharge from the UMC St Radboud. Our discharge 
policy is described in our previous report.7 It is, however, important to realize that none of the 
deaths occurring during the post-discharge period occurred after transfer to their cardiac 
centre and thus would not be considered a hospital death directly related to the operation. The 
studied variables and their definition were presented in table 1.   
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Table 1 Variables and their definition 
Age (years) 3 groups: age < 60, 60 ³ age <70, age ³ 70 years 
Sex Male, Female  
Obesity Body Surface Area (BSA) > 2.1 
Diabetes Diet-controlled, oral therapy or insulin dependent diabetes 
Hypertension Systolic blood pressure > 160 mmHg, or diastolic pressure > 100 mmHg. Or antihypertensive medication.  
Hyperlipidemia  Total cholesterol > 250mg/dl or triglyceride level 200 mg/dl 
Vascular disease Peripheral -, abdominal vascular pathology or operation 
Neurological disease Cerebrovascular accidents and /or transient ischemic attack 
Renal disease Renal failure (creatinine ³ 150 mmol /L) preoperative dialysis, renal transplantation 
Lung disease Chronic obstructive pulmonary disease and/or history of previous lung disease 
PTCA History of previous percutaneous transluminal coronary angioplasty 
Preoperative myocardial 
infarction (MI) History of myocardial infarction before the first operation 
Between myocardial 
infarction (MI)  
History of myocardial infarction between the first operation and the 
reoperation. 
Rhythm Preoperative sinus rhythm 
Internal mammary artery 
graft (IMA-graft) Patent IMA graft at the reoperation 
Operative status 
3 groups: Elective: patients with stable cardiac function, usually 
scheduled at least one day prior to the surgical procedure. Urgent: 
surgery is required within 24 hours after admission, Emergency: 
operation for evolving infarction, ischemia not responding to medical 
therapy, or cardiogenic shock. 
Mild valve pathology Combined valve disease, not requiring surgical intervention 
ECC ECC: extra corporal circulation, duration in minutes 
AoX AoX; aortic cross clamp, duration in minutes 
Perioperative myocardial 
infarction (peri-MI) A new Q wave and a CPK-MB% ³ 10% 
 
2.2 Surgical technique 
Our surgical technique is described in previous papers.5-8 Mean bypass time was 140 ± 
60.8 minutes (range 25-485), and mean duration of aortic cross-clamping was 70 ± 33.6 
minutes (range 10-227). There was a mean of 2.4 ± 0.8 grafts (range 1-5), and a mean of 3.2 ± 
1.2 (range 1-7) distal  anastomoses. Of the used grafts 1.0 ± 0.6 (range 1-2) were arterial 
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grafts with 1.2 ± 0.9 (range 1-5) distal anastomoses and 428 patients (79.1 %) received at least 
one new arterial graft. It is important is to realize that since 1993, cardioplegia has mostly 
been delivered using retrograde techniques in RECABG. 
 
2.3 Statistical analysis 
The statistical method is the same as in our previous study.8 To test which variables 
can be considered risk factors for early out-of-hospital mortality, but also for the operative 
related risk factors, Fisher’s exact test  (unifactor analysis) was used. Multiple logistic 
regression analysis was used to identify risk factors that independently contributed to 
increased or decreased risk.  A p-value of  p £  0.05 was considered as significant. 
To construct a predictive model for early out-of-hospital mortality, the odds ratio’s 
derived from the parameter estimates in the logistic regression analysis were considered 
estimates of relative mortality risk. To identify a subset of variables with prognostic value for 
early out-of-hospital mortality a stepwise selective procedure was used at a significance level  
p £  0.05 (significant level for entry respectively stay into the prognostic model). A receiver 
operating characteristics curve (ROC) was calculated to measure the prognostic value of this 
subset.  This subset was then used to calculated a prognostic score ‘S’ and a predicted 
probability ‘P‘ for early out-of-hospital mortality.  The prognostic score ‘S’ is a linear 
function of the variables included in the selected subset. If the variables are selected the ‘S’-
score is represented by S=b0+b1X1+b2x2+….. bhxh. The predicted probability (P) for early 
out-of-hospital mortality is calculated by P= 1/1+e-s.   Sensitivity analysis, ( 2´2 table)  was 
used for evaluating the effect of the initial estimate on the final decision.  
  
2.3 Perioperative myocardial infarction 
 Because of the importance of the variable perioperative myocardial infarction for the 
early out-of-hospital mortality we performed an uni- and multivariate analysis to identify 
independent variables for a perioperative myocardial infarction. The total group of 541 
patients was used for this ana lysis. 
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Table 2.  Unifactor analysis of pre - and perioperative variables.  
(Only statistical significant variables were presented)   
  Early out-of-hospital mortality Perioperative myocardial infarction 
  Patients N=505 
 
N=39 (7.7) 
Patients 
N=541 
 
N=89 (16.9) 
Variable  Category N (%) N (%) p-value N (%) N (%) p-value 
Diabetes No 414 (82) 18 (4.3) 10-7 445 (82) 69 (15.5) 0.22 
 Yes 91 (18) 21 (23.4)  96 (18) 20 (20.8)  
Hypertension No 194 (38) 6 (3.0) 0.002 208 (38) 32 (15.3) 0.63 
 Yes 311 (62) 33 (10.6)  333 (62) 57 (17.1)  
Vascular disease No 400 (79) 20 (5.0) 10-5 423 (78) 61 (16.8) 0.02 
 Yes 105 (21) 19 (18.1)  118 (22) 28 (24)  
Renal disease No 493 (98) 35 (7.5) 0.01 528 (98) 86 (16.2) 0.45 
 Yes 12 (2) 4 (13.3)  13 (2) 3 (23)  
Lung disease No 409 (81) 19 (4.6) 3.10-6 436 (81) 65 (17.5) 0.05 
 Yes 96 (19) 20 (20.8)  105 (19) 24 (29.6)  
Between M.I. No 381 (75) 23 (6.0) 0.04 397 (73) 55 (13.8) 0.009 
 Yes 124 (25) 16 (13)  144 (27) 34 (29.8)  
IMA-graft No 432 (86) 38 (8.8) 0.03 467 (86) 80 (17.10 0.31 
 Yes 73 (14) 1 (1.8)  74 (14) 9 (12.1)  
Operative status Elective 278 (55) 9 (3.2) 10-9 289 (53) 40 (13.8) 0.000 
 Acute 184 (36) 15 (8.1)  198 (37) 29 (14.6)  
 Emergency 43 (9) 15 (34.8)  54 (10) 20 (37.0)  
Mild valve 
disease No 464 (92) 32 (6.9) 0.03 
495 (91) 75 (15.1) 0.01 
 Yes 41 (8) 7 (17)  46 (9) 14 (43.7)  
ECC-time (min) <120 207 (41) 9 (4.3) 0.02 212 (39) 32 (15.0) 0.08 
 ³120 298 (59) 30 (10)  329 (61) 57 (17.3)  
Myocardial 
protection 
Retrograde 
 207 (41) 16 (7.7) 1.00 
305 (57) 32 (10.4) 0.000 
 Antegrade 294 (58) 23 (7.7)  230 (42) 56 (24.3)  
 Other* 4 (1)   6 (1) 1  
Perioperative MI No 442 (88) 19 (4.2) 2.10-8    
 Yes 63 (12) 20 (32)     
*Other  technique, not incorporated in the analysis concerning myocardial protection, because of the 
limited number of patients. 
ECC: extra corporal circulation, MI: myocardial infarction 
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3. Results 
3.1 Early out-of-hospital mortality 
Early out-of-hospital mortality is 7.7% (39/505 patients).  In 34 patients mortality was 
cardiovascular related, in five patients the cause of death is noted as uncertain.8 Table 2 
presents the statistical significant variables of the unifactor risk analysis. Risk factors for early 
out-of-hospital mortality are: diabetes (p=10-7), hypertension (p=0.002), vascular disease 
(p=10-5), renal disease (p=0.01), lung disease (p=3.10-6), between-myocardial infarction ( 
p=0.02), no patent IMA graft ( p=0.03), No-elective operation ( p=10-9), mild valve disease 
(p=0.03), ECC-time ³ 120 minute (p=0.02) and a perioperative myocardial infarction 2.10-8. 
Multifactor risk analysis (table 3) identified, in order of importance, perioperative myocardial 
infarction (p=0.0001), emergency operation ( p=0.0001), diabetes (p=0.002), and lung disease 
(p=0.05) as independent risk factors for early out-of-hospital mortality. The odds ratio’s 
(estimates of relative risk) are 15.6,15.4,5.1 and 2.8. respectively. 
 
Table 3. Multifactor risk analysis, logistic regression analysis, for early out-of-hospital mortality  
 N=39 (7,7)  
Preoperative variable  Odds Ratio p-value 
Age < 60 years 0.76 0.65 
Age ³ 70 years 1.3 0.70 
Sex (female/male) 0.59 0.31 
Obesity (yes/no) 0.70 0.54 
Diabetes (yes/no) 5.1 0.002 
Hypertension (yes/no) 0.97 0.96 
Hyperlipidemia (yes/no) 0.9 0.81 
Vascular disease(yes/no) 1.4 0.50 
Neurological disease (yes/no) 1.9 0.36 
Renal disease (yes/no) 1.9 0.52 
Lung disease (yes/no) 2.8 0.05 
PTCA (yes/no) 0.89 0.85 
Previous M.I. (yes/no) 1.5 0.43 
Between M.I. (yes/no) 1.7 0.34 
Sinus rhythm (yes/no) 2.9 0.19 
Patent-IMA-graft (yes/no) 0.18 0.13 
Acute operation (versus elective) 2.1 0.17 
Emergency operation  (versus elective) 15.4 0.0001 
Time period ’87-’92 /’93-‘98 0.65 0.46 
Mild valve disease 0.62 0.56 
ECC-time ³120 minutes 2.4 0.12 
Aox-time ³ 60 minutes 0.4 0.06 
Perioperative myocardial infarction 15.6 0.0001 
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3.2  Prediction of early out-of-hospital mortality 
Using stepwise logistic regression analysis, the following variables were selected for  
prediction of early out-of-mortality: diabetes, lung-disease, emergency operation, and 
perioperative myocardial infarction. The associated regression coefficients (bi), odds ratio’s, 
and p-values are presented in table 4.  
 
Table 4. Stepwise logistic regression analysis.  
Variables selected for prediction of early out-of-hospital mortality.  
Preoperative variable  Regression bi 
coefficient (±SE) 
Odds Ratio p-value 
Intercept -4.43 (0.39)   
Diabetes (yes/no) 1.54 (0.43) 4.7 3.10-4 
Lung disease(yes/no) 1.28 (0.43) 3.6 0.003 
Emergency operation  (versus elective) 2.28 (0.48) 9.8 1.10-4 
Myocardial infarction 2.45 (0.44) 11.6 1.10-4 
 Note: area under the ROC =0.86.  
 
The ROC curve gave an area under the curve value of 0.86. The S –score for an individual 
patient is calculated as follows:  S= - 4.43  + 1.54 (diabetes) + 1.28 (lung disease) + 2.28 
(emergency operation) + 2.45 (perioperative myocardial infarction). 
The distribution of the S-scores and predicted probabilities P for early mortality in the 
group with  (n=39) and without  (n=466) early out-of-hospital mortality is presented in table 
5a and 5b.  
 
Table 5a. Distribution of the S-scores in group of patients with (n=39) and without (n=466) early 
out-of-hospital mortality  (s -score classified into discrete classes). 
 S-score  
Group -4 -3 -2 -1 0 1 2 3  
No early out-hospital mortality 
% 
285 
(61) 
96  
(21) 
67  
(14) 
9  
(1.9) 
6  
(1.3) 
3 
(0.6) 
0  
(0) 
0 466 
Early out-hospital mortality 
% 
5  
(13) 
3  
(8) 
10  
(26) 
5  
(13) 
3  
(7.7) 
7  
(18) 
2  
(5.1) 
4  
(10) 
39 
Note: score –2 means (-2.5) – (-1.5) 
 
The Scores are classified into the following classes: -4 (-4.5) – (-3.5); -3: (-3.5) – (-2.50) …. 
3: (2,5) – (3.5). For the probability, following classification is used: 0:  0£ P< 0.10; 1: 
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0.10£P<0.20; … :0.90£P<1.00. The observed probabilities in these discrete classes compare 
well with the mid-points of the predicted probabilities (table 5b)  
 
Table 5 b. Distribution of predicted probabilities ( P) in group of patients with (n=39) and 
without (n=466) early out-of-hospital mortality. Classes defined as: 0 = 0£P<0.10; 1= 
0.10£P<0.20; … 8=0.80£P<0.90 
 Predicted probability  
 0 1 2 3 4 5 6 7 8 9 
No out-hospital mortality 
(%) of the total (n=466) 
381 
(82) 
67 
(14) 
4  
(0.9) 
10  
(2.2) 
0 1 
(0.2) 
2 
(0.4) 
1 
(0.2) 
0 0 
Early out-hospital mortality 
(%) of the total (n=39) 
8  
(21) 
10 
(26) 
1  
(3) 
5 
(13) 
0 
 
2 
(5) 
2  
(5) 
5  
(13) 
2  
(5) 
4 
(10) 
Observed out-hospital mortality  
(%) 
2.1 13 20 33 0 67 50 83 100 100 
 
We decide to classify patients in low risk, intermediate risk, high risk and very high 
risk patients (table 6). The a priori average risk of early out-of-hospital mortality is 39/505 
(7.7%). Using the S-score and the predicted probability P, we classify patients in low risk  
(5%), intermediate risk  (15%), high risk (30 %), and very high risk (40%). The observed 
mortality in these risk groups compare well with the predicted (2.1%, 13%, 30%, 79%).   
 
Table 6. Classification of patients in low risk, intermediate risk, high risk and very high risk 
patients. 
 Risk category  
 Low Intermediate High Very high  
Predicted probability 5% 15% 30% ³ 40%  
Class 0£P<0.10 0.10£P<0.20 0.20£P<0.40 p³0.40  
No out-hospital  mortality 381 67 14 4 466 
Early out-hospital mortality 8 (2.1%) 10 (13%) 6 (30%) 15 (79%) 39 
TOTAL  389  77 20 19 505 
 
We use a predicted probability P³0.40 (risk category very high ) as a cut-off point for 
constructing a prognostic test for early out-of-hospital mortality. The specificity of the test  is 
high (0.99), but a low sensitivity  ( 0.39). The predictive value of a positive respectively 
negative test are respectively 0.79 and 0.95 (Table 7).     
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Table 7. 2x2 table for the evaluation of the early out-hospital mortality prediction 
 
 
 
 
 
 
 
 
 
 
 
3.3 Perioperative myocardial infarction. 
Of the four identified independent predictors of early out-hospital mortality, only a  
perioperative myocardial infarction is a real influenceable surgical variable.  Of the total 
group of 451 patients, 89 patients (16 %) had a perioperative myocardial infarction. Table 2 
presents the results of the unifactor risk analysis. Vascular disease (p= 0.02), between-
myocardial infarction (p=0.009), emergency operation (p=0.000), mild valve disease (p=0.01) 
and myocardial protection method ( p=0.000) are statistical significant risk factors  for a 
perioperative myocardial infarction. Multivariate analysis identified emergency operation 
(p=0.001) with an Odds Ratio of 1.7 and myocardial protection (p=0.0000) with an Odds 
Ratio of 3.7 as independent factors for a perioperative myocardial infarction.    
  
4. Discussion 
 
The high mortality rates of RECABG, described in several studies, prove that 
RECABG remains high risk surgery.1-6 Estimation of the risk of these operations is essential 
not only for the decision as to whether or not to perform the RECABG or not, but also to 
inform the patient and family about their risk. Important is that based on the work of 
Blackstone we predict early- six months- mortality, because certainly in high risk patients, the 
postoperative phase is prolonged and influenced by patient- and procedural- related 
variables.9 In a previous study we discussed a predictive model for early mortality, 
constructed with preoperative variables.8 We must realize that patients preoperatively 
 Prognostic test  
Early Mortality T=0 
P< 0.40 
T=1 
P³ 0.40 
 
No (D=0) 462 4 466 
Yes (D=1) 24 15 39 
 486 19 505 
    
Sensitivity : P[T=1/D=1] = 15/39 = 0.39  
Specificity: P[T=0/ D=0] = 462/466 = 0.99  
Predictive value of positive test: P[D=1/T=1] = 15/19 = 0.79 
Predictive value of negative test: P[D=0/T=0] = 462/486 = 0.95 
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informed about their risk for early mortality who survive the RECABG, are postoperatively 
interested in what is changed. But what is even more important for cardiologists, family 
doctors, and others concerned with these patients in the first months postoperatively, is to 
know which patients are at risk for mortality during these first months. Additionally we 
studied the risk factors of this out-of-hospital mortality, and especially a perioperative 
myocardial infarction, to see if we could decrease this out-of-hospital mortality.  
The cause of death of our 39 out-of-hospital deaths was cardiovascular-related in 34 
patients (87 %). In five patients the cause of death was registered as uncertain. This means 
that we could not trace, even after contacts with cardiologists, family doctor, and the patients 
family, whether the cause of death is cardiac or not cardiac related. However, we incorporated 
these five patients in our analysis, because a not-cardiac related death was not proven.  
We studied a number of variables, but the list is of course not all- inclusive. Probably 
the most important variable not discussed is the ejection fraction. The influence of an 
impaired left ventricular function on the operative result of myocardial revascularization has 
been proven in several studies.1-6 However, in our studied population it was seldom registered 
preoperatively and therefore not included in the analysis. Left main stenosis and vessel 
disease, are not incorporated in the analysis, because in RECABG, these variables are difficult 
to define. What is the meaning of a left main in a patient with a patent, or even, a diseased 
graft to the LAD, what is the meaning of three-vessel disease in patients with (diseased) grafts 
to several coronary arteries? Definition of completeness of revascularization in RECABG, is 
also a problem. Vessel indication can be difficult: for instance a decision not to replaced old 
patent, but (minimally?) diseased grafts, because the native coronary artery is in such a bad 
condition that problems can be expected. These are specific problems of RECABG, but 
related to the completeness of the revascularization. Other specific variables, not discussed, 
are, the degree of vein graft stenosis, the number of arterial and vein grafts.  
 
Early Out-of- hospital mortality 
Unifactor analysis identified diabetes, hypertension, lung-, vascular-, renal disease, 
between MI, No-patent IMA-graft, operative status, mild valve disease, ECC > 120 minutes, 
and a perioperative myocardial infarction as risk factors for early out-hospital mortality. Pre-
myocardial infarction, no-sinus rhythm, risk factors for early mortality,8 were not identified as 
significant for early out of hospital mortality.  
Using stepwise logistic regression analysis, diabetes, lung disease, emergency 
operation and a perioperative myocardial infarction were identified as independent risk factors 
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predictive for early out-of- hospital mortality. The variables were discussed in our previous 
paper,7 there is only a minimal difference in statistical significance because in the present 
paper, we include only the 505 discharged patients in our analysis.     
 
Predictive model for early out-of-hospital mortality 
Independently of forwards or backwards performed regression analysis the variables, 
diabetes, lung disease, emergency operation and perioperative myocardial infarction, were 
selected. The area under the ROC curve (0.86) indicates that good discrimination remains 
between whether or not early out-of-hospital mortality occurs. In contrast to our predictive 
model for early mortality,8 where we had seven variables, we have only four variables here.  
  By using these four variables we created a risk score. We classified patients in low risk 
(5%), intermediate risk (15%), high risk (30%) and very high risk (40%) for early mortality. 
The observed mortality in these risk groups compares well with the predicted (table 6). The 
specificity of our test is high, as required for a prognostic test, but we have a low sensitivity. 
Still the test is useful for selecting patients with a very high risk on out-of-hospital mortality. 
The predictive value of a positive and negative test are respectively 0.79 and 0.95, 
respectively (table 7). This means that if the test is negative, there is only 5 % risk on early 
out-of-hospital mortality on the other hand, if the test is positive, there is 79 % risk that the 
patient will die during the early out-of- hospital period.   
 It is important to realize that the specificity of our test is high for very high risk 
patients, however, this is of course a limited number of patients (15/39). A point of criticism 
can be that the majority of patients (24/39) were missed.  However, the aim of a predictive 
model is to provide information for us and the patients about the probability of the risk of 
mortality and in the first place it is this information that is important. It is not the intention to 
predict the specific outcome of an individual patient, but it can be important to know if a 
patient has a low or very high risk for mortality in the first coming months. Another 
interesting point, is that most patients died of a cardiac related cause. This information is 
retrieved from families, doctors or cardiologists and registered as cardiac-, not cardiac-related, 
or unknown. More detailed information, can probably result in specific therapy, such as anti-
arrhythmic therapy if it is known that arrthythmias are responsible for many these cardiac 
deaths. But this needs further analysis, in a complex and limited patient population.     
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Perioperative myocardial infarction 
Of the four identified independent variables, a perioperative myocardial infarction is 
the only variable that can be influenced by surgery. We exclude emergency operation as an 
influenceble variable, because we can only take the decision to operate or not to operate an 
emergency patient and the variables lung-disease and diabetes are patient-characteristics.  
Unifactor analysis identified vascular disease, between MI, operative status, mild valve 
disease, and ante/retrograde delivery of cardioplegia as risk factors for a perioperative 
myocardial infarction. Multivariate analysis identified operative status (as well emergency 
and urgent operation) and ante/retrograde delivery of cardioplegia as independent factors for a 
perioperative myocardial infarction. The importance of retrograde delivery of cardioplegic 
solution in RECABG is wellknown.5-8,10 We realize that there are several benefits of 
retrograde delivery of cardioplegia: better distribution in the myocardium, also distal of 
arterial grafts, and a decrease in the risk of atheroembolism dur ing manipulation. But we also 
realize that other factors, as incomplete revascularization, extent of coronary disease, are 
important and are not incorporated in our study.  However, this means that retrograde delivery 
of cardioplegia, identified as a variable influencing hospital mortality,7 is also  important for 
the reduction of out-of-hospital mortality of RECABG. Therefore we agree with Borger et 
al.,10 and recommend the routine use of retrograde cardioplegia during RECABG.   
 
This study and our previous analysis of early mortality,8 resulted in two predictive 
models: one preoperatively helpful in decision-making as to whether or not to reoperate, the 
present, useful for identifying patients at risk for out-of hospital mortality. These two 
predictive models, provide informations for patients, their families and doctors in two 
completely different situations.  
 
In conclusion; in this study we identified independent predictors of early out-of-
hospital mortality and with our predictive model we can stratify patients surviving the 
RECABG, according to their risk for early out-of-hospital mortality.  To decrease this out-of-
hospital mortality we recommend the use of retrograde cardioplegia.         
 
* We thank Johannes M van Druten, PhD, department of Medical Informatics, Epidemiology and Statistics, 
University of Nijmegen, for the statistical analysis.  
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Abstract 
 
Objective: Despite advances in cardiac surgery, the risk of reoperative coronary artery bypass 
surgery  (RECABG) still exceeds those of a primary myocardial revascularization and also 
the late results are not so favourable. In this study long term cardiac survival is analyzed. 
Methods:  We analyzed long term cardiac survival of 466 patients who survived the first six 
months after a RECABG between January 1987 and December 1998. Actuarial survival 
estimates were calculated and pre- and peroperative variables were analyzed to identify 
predictors of long term cardiac related mortality. 
Results: Mean follow-up was 7.7 ± 3.8 years (1-17 years), and follow-up was 95.6% 
complete. One years cardiac survival was 98.2%, 5-year: 91.0%, 10-year: 78.7% and 14-year 
survival 60.2%. Cardiac survival was only significant superior for patients under 65 years of 
age at the moment of the RECABG. Impaired left ventricular function was identified as the 
only independent predictor of late cardiac-related mortality.  
Conclusion: The long term survival in patients undergoing RECABG is acceptable. Once 
patients survived the first six postoperative months, advanced age (> 65 years) is affecting 
long term cardiac survival and impaired left ventricular function is the only independent 
predictor of late cardiac mortality 
 
Keywords  
Coronary, reoperation, cardiac survival, 
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1. Introduction. 
 
Patients undergoing reoperative coronary artery bypass surgery (RECABG) have 
higher mortality, perioperative as well as at long term, compared with patients undergoing a 
primary myocardrevascularization ( CABG). [1-4] Since the study of Blackstone, using 
hazard function methology for time-related events, it is clear that risk factors must be 
identified for each phase of hazard. [5]  In previous articles we focussed on mortality in the 
early- 6 months- phase after RECABG. [6,7] The present study concerns the longterm 
survival of the patients surviving the early postoperative phase after RECABG. This is in 
contrast with most other studies evaluating long term results starting their ‘long-term-
analysis’ at the moment of the operation or hospital discharge.   
 
2. Material and methods  
2.1 Patients 
 With the aid of our database, Coronary Surgery Database Radboud Hospital 
(CORRAD), a registry that stores pre-, peri-, postoperative and follow-up data on all patients 
undergoing isolated coronary bypass grafting, we identified a series of 541 patients 
undergoing a first RECABG from January 1987 to December 1998 at the UMC St. Radboud 
Nijmegen.  
The clinical indication for RECABG was angina and proven ischemia despite medical 
therapy with b blockers, calcium antagonists or nitrates, or a combination. We distinguish 
three groups: (1) elective operations, patients with stable cardiac function, usually scheduled 
at least one day prior to the surgical procedure; (2) urgent operations, when surgery is 
required within 24 hours after admission; and (3) emergency operations: in case of operation 
for evolving infarction, ischemia not responding to medical therapy, or cardiogenic shock.  
Probably due our restrictive attitude for PTCA of diseased vein grafts , only two patients were 
operated in emergency after a failed PTCA. Forty-one patients (7.5%) were reoperated for 
early graft failure, 130 patients (24.1%) for late graft failure, 49 patients (9.1) for progression 
of athersosclerosis in the native coronary system, 314 patients (58.1%) for a combination of 
late graft failure and  progression of athersosclerosis in the native coronary system, and 7 
patients ( 1.2%) for incomplete revascularization. The mean interval between the CABG and 
RECABG was 141±59 months (0-300). 
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Table 1.  Definitions and frequencies of variables 
Variable  Category 
 
Definition 
 
Patients  
N= 466 
   N (%) 
Age (years) age < 65, and age  ³ 65 years <65 / ³65 265(59) / 181(41) 
Sex Male, Female  Fem / Male  88 (19) / 378 (81) 
Diabetes Diet-controlled, oral therapy or insulin dependent diabetes No / Yes 396 (85) / 70 (15) 
Hypertension 
Systolic blood pressure > 160 mmHg, or diastolic 
pressure > 100 mmHg. Or antihypertensive 
medication.  
No / Yes 188 (40) / 278 (60) 
Hyperlipidemia  Total cholesterol > 250mg/dl or triglyceride level 200 mg/dl No / Yes 195 (42) / 271 (58) 
Vascular disease Peripheral -, abdominal vascular pathology or operation No / Yes 380 (81)/ 86 (19) 
Neurological 
disease 
Cerebrovascular accidents and /or transient 
ischemic attack No / Yes 440 (84) / 26 (6) 
Renal disease Renal failure (creatinine ³ 150 mmol /L) 
preoperative dialysis, renal transplantation 
No / Yes 458 (98) / 8 (2) 
Lung disease Chronic obstructive pulmonary disease and/or history of previous lung disease No / Yes 390 (84) / 78 (16) 
PTCA History of previous PTCA No / Yes 398 (85) / 68 (15) 
Pre-M.I. History of M.I. before the first operation No / Yes 190 (31) / 276 (59) 
Between M.I. History of myocardial infarction between the first operation and the reoperation. No / Yes 358 (77) / 108 (23) 
Sinus rhythm Preoperative sinus rhythm No / Yes 23 (0.5) / 443 (99.5) 
IMA-graft Patent IMA graft at the reoperation No / Yes  394 (84) / 72 (16) 
Impaired left 
ventricular 
function 
Ejection fraction <30% or indicated by the 
surgeon at the moment of the reoperation No / Yes 426 (91) / 40 (9) 
Elective 269 (58) 
Acute 169 (36) Operative status 
Elective: patients with stable cardiac function, 
usually scheduled at least one day prior to the 
surgical procedure. Urgent: surgery is required 
within 24 hours after admission, Emergency: 
operation for evolving infarction, ischemia not 
responding to medical therapy, or cardiogenic 
shock. 
Emergency 28 (6) 
Mild valve 
disease 
Combined valve disease, not requiring surgical 
intervention No / Yes 432 (93) / 34 (7) 
Retrograde 270 (58) 
Antegrade 191 (41) 
Myocardial 
protection 
Way of delivery the cardioplegic solution 
Other* 5 (1) 
IMA-total Presence of at least one arterial graft (mostly internal mammary artery), after the reoperation  No /Yes  66 (10) / 400 (90) 
Perioperative  MI A new Q wave and a CPK-MB% ³ 10% No / Yes 413 (89) / 53 (11) 
PTCA: percutane transluminal coronary angioplasty, M.I.: myocardial infarction, IMA: internal 
mammary artery. 
*Other  technique, not incorporated in the analysis concerning myocardial protection, because of the 
limited number of patients. 
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Hospital mortality 36/541 (6.7%) and early phase – 6-months - mortality 75/541 
patients (13.9%) were the subject of our previous studies.[6,7] The 466 surviving patients 
were entered in this follow-up study. The studied pre- and peri-operative variables were listed 
in table 1.  
To be able to compare our survival rates with other studies, we also calculated survival 
for the total patient population (541 patients) starting from the operation. 
 
2.2 Follow-up  
 Follow-up information is based on data from cardiologists, family doctors, and an 
annual survey sent directly to the patients. A cross sectional follow-up was performed in 
December 2002. If there was no response from the patient, the information was traced by 
telephone contact with the patient, family, doctor, or government records. In case of death, the 
cardiologist, family doctor, or patients family was contacted to identify the cause of death.  
 
2.3 Statistical analysis 
 Actuarial survival estimates were calculated using Kaplan-Meier method and 
compared using the log-rank test. Univariate analysis and multiple logistic regression analysis 
were used to identify risk factors that independently predicted long term cardiac-related 
mortality. A P-value of 0.05 or less was considered significant.  
 
3. Results 
 
Four hundred sixty-six patients with a mean age of 63.4 ± 8.4 years (median 64, range 
32-91) were included in the follow-up. Follow-up was 95.6% complete, 20 patients were lost 
for follow-up. Mean follow-up was 7.7 ± 3.8 years, median 7.0 years and a range of 1-17 
years. There were 138 late deaths: in 89 patients there was a proven cardiac related death, in 4 
patients the cause of death was unknown, however these deaths were computed as cardiac 
deaths. Thus, we have 93 patients (67.4%) with a cardiac related death. In the other 45 
patients (22.6%) death was of non-cardiac cause, 21 of them died of cancer.  
The total one-year survival is 97.3%, 5-year: 86,8%, 10 year:  68.6% and a 14-year 
survival of 48.1%. The cardiac survival is presented in figure 1. The one- year cardiac 
survival is 98.2%, 5-year: 91.0%, 10-year: 78.7% and a 14-year survival of 60.2%.  
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Figure 1. Cardiac survival for survivors of the early postoperative phase after reoperative 
coronary bypass surgery.  
 
 
 
Figure 2. Cardiac survival divided by age. (P=0.002 , log rank test) 
Dotted line patients younger than 65 years  
Full line patients aged 65 years or older.  
 
 1-year 5-years 10-years 14-years 
Survival (%) 98.2 91.0 78.7 60.2 
Patients at risk 438 333 141 23 
 1-year 5-years 10-years 14-years 
<65 years     
Survival (%) 98.1 93.7 82.8 66.6 
Patients at risk 260 216 107 20 
³ 65 years      
Survival (%) 98.3 86.9 70.7 44.2 
Patients at risk 178 117 34 3 
  
97  
 
Cardiac survival was only significantly superior for patients under 65 years old 
compared to older patients (P=0.002) (figure 2) for the other studied variables (Table 2) there 
was no significant difference in survival. 
 
Table 2. Studied variables tested for their association with long term cardiac survival and P-
value (log-rank test)             
Variable  Category P-value  
Age (years) <65 / ³65   0.002 
Sex Male/ Female  0.07 
Diabetes Yes / No 0.06 
Hipertensión Yes / No 0.65 
Hyperlipidemia  Yes / No 0.12 
Vascular disease Yes / No 0.12 
Neurological disease Yes / No 0.21 
Renal disease Yes / No 0.69 
Lung disease Yes / No 0.53 
PTCA Yes / No 0.79 
Pre-M.I. Yes / No 0.48 
Between M.I. Yes / No 0.76 
Sinus rhythm Yes / No 0.65 
IMA-graft Yes / No 0.18 
Impaired left ventricular function Yes / No 0.07 
Operative status Elective / acute/ emergency 0.84 
Mild valve disease Yes / No 0.31 
Myocardial protection Antegrade / Retrograde 0.61 
IMA-total Yes / No 0.35 
Perioperative  MI Yes / No 0.88 
 
To be able to compare our survival rates with other studies, we also calculated survival 
for the total patients population (541 patients) starting from the operation. This resulted in a 
one-year survival of 83.8%, 5-year: 76.9% and a 10-year survival of 60.6%. Cardiac survival 
was 84.8%, 78.5%, and 66.5%, respectively.  
Univariate analysis identified impaired left ventricular function (P=0.02) and mild 
valve disease (P=0.04) as two variables related with late cardiac mortality (Table 3). Impaired 
left ventricular function is identified by multivariate analysis (Table 4) as the only 
independent variable for late cardiac mortality (P=0.021)    
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Table 3 Results of uni-variate analysis for long term cardiac related mortality (N=446 patients) 
Variable  Category Live N (%) Mortality N (%) P-value  
Age (years) <65  215 (81.1) 50 (18.9) 0.21 
 ³65 138 (76.2) 43 (23.8)  
Sex Female 62 (73.8) 22 (26.2) 0.18 
 Male 291 (80.4) 71 (19.6)  
Diabetes No 306 (80.1) 76 (19.9) 0.22 
 Yes 47 (73.1) 17 (26.6)  
Hypertension No 145 (81.0) 34 (19) 0.42 
 Yes 208 (77.9) 59 (22.1)  
Hyperlipidemia  No 144 (76.6) 44 (23.4) 0.25 
 Yes 209 (81.0) 49 (19.0)  
Vascular disease No 291 (80.4) 71 (19.6) 0.18 
 Yes 62 (73.8) 22 (26.2)  
Neurological disease No 335 (79.6) 86 (20.4) 0.36 
 Yes 18 (72.0) 7 (28.0)  
Renal disease No 347 (79.0) 92 (21.0) 0.66 
 Yes 6 (85.7) 1 (14.3)  
Lung disease No 295 (79.3) 77 (20.7) 0.85 
 Yes 58 (78.4) 16 (21.6)  
PTCA No 300 (78.5) 82 (21.5) 0.43 
 Yes 53 (82.8) 11 (17.2)  
Pre-M.I. No 144 (78.7) 39 (21.3) 0.84 
 Yes 209 (79.5) 54 (20.5)  
Between M.I. No 273 (79.8) 69 (20.2) 0.52 
 Yes 80 (76.9) 24 (23.1)  
Sinus rhythm No 18 (78.1) 5 (21.9) 0.91 
 Yes 335 (79.2) 88 (20.8)  
IMA-graft No 299 (79.1) 79 (20.9) 0.95 
 Yes 54 (79.4) 14 (15.1)  
No 327 (80.5) 79 (19.5) 0.021 Impaired left 
ventricular function Yes 26 (65.0) 14 (35.0)  
Operative status Elective 200 (78.7) 54 (21.3) 0.86 
 Acute 134 (80.2) 33 (19.8)  
 Emergency 19 (76) 6 (24)  
Mild valve disease No 328 (79.6) 84 (20.4) 0.04 
 Yes 25 (73.5) 9 (9.7)  
Myocardial protection Retrograde 210 (81.4) 48 (18.6) 0.35 
 Antegrade 138 (75.8) 44 (24.2)  
IMA-total No 32 (69.6) 14 (30.4) 0.09 
 Yes 321 (80.3) 79 (19.8)  
Perioperative  MI No 326 (79.5) 84 (20.5) 0.52 
 Yes 27 (75.0) 9 (9.7)  
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Table 4 Results of the multivariant analysis of late cardiac-related mortality 
Variable Category Odds Ratio P-value 
Age (years)  ³65 / <65  1.3 0.28 
Sex Female / Male 0.7 0.99 
Diabetes Yes / No 1.3 0.36 
Hipertensión Yes / No 1.2 0.42 
Hyperlipidemia Yes / No 0.7 0.19 
Vascular disease Yes / No 1.3 0.37 
Neurological disease Yes / No 1.4 0.44 
Renal disease Yes / No 0.4 0.44 
Lung disease Yes / No 1.0 0.99 
PTCA Yes / No 0.7 0.38 
Pre-M.I. Yes / No 0.8 0.55 
Between M.I. Yes / No 1.2 0.53 
Sinus rhythm Yes / No 1.0 0.91 
IMA-graft Yes / No 1.5 0.32 
Impaired left ventricular function Yes / No 2.5 0.02 
Operative status Elective / Acute+ Emergency. 1.3 0.6 
Mild valve disease Yes / No 1.5 0.34 
Myocardial protection Retro- / Ante-grade 0.7 0.83 
IMA-total Yes / No 0.3 0.19 
Perioperative  MI Yes / No 1.2 0.66 
 
 
4. Discussion.  
 
 Based on the work of Blackstone, using hazard function methodology for the 
occurrence of a time related event, as postoperative death, a three phase hazard function was 
identified. An early phase, during the first postoperative months, prolonged in high risk 
patients and influenced by patient and procedural related variables, a constant and a late 
phase. [5,8] In our previous work we analysed the occurrence of mortality during the early 
phase after RECABG.[6,7] In  the present  study we analyzed  long term survival of patients 
undergoing a RECABG, because each phase has his own risk factors. We started our survival 
analysis at the end of the early phase, six months postoperative. This is different from other 
survival studies, and consequently it is difficult to compare our results with these studies.[9-
17] Therefore we also calculated survival for our entire patient population.  
Table 5 gives a review of different survival studies. Studied period, number of 
patients, age, mortality, patients included in follow-up, and 5-yrs and 10-years survival are 
summarized. Because some studies give reviews over different periods, the indicated age is 
only approximate.[11,12 ]  
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Table 5. Review of survival studies. 
 
Study  
(reference) 
Studied period 
No of patients – Mean age  
Mortality Patients included  
in follow-up 
Survival % 
5 yrs   10 yrs  
Salomon et al. 
(1) 
1970-1988 
508pts - 59yrs 
30-days: 
6.9% 
All patients 
30-day-survivors 
80  
87.4 
65 
70 
Lyttle et al. 
(12) 
1967-1984 
1500 pts - ± 56 yrs 
Hospital: 
±:3.4% 
Hospital survivors 90 75 
Yamarmuro et al. 
(15) 
1983-1993 
739 pts ( >70 yrs) - 74yrs 
Hospital: 
7.6% 
Hospital survivors 75 49 
Shapira et al. 
(17) 
1978-1989 
498 pts – 64.6 yrs 
30-days: 
3% 
All patients 90 74 
Loop et al. 
(12) 
1967-1987 
2500 pts - ± 57 yrs 
Hospital: 
± 3% 
Hospital survivors  63.4 
Blanche et al. 
(16) 
1983-1996 
49 pts >80 yrs - 82 yrs 
Hospita l : 
8% 
Hospital survivors 58  
Weintraub et al  
[I] (14) 
1975-1993 
2030 pts - 61 yrs 
Hospital : 
7% 
All patients 76 55 
Weintraub et al. 
[II] (14) 
1975-1993 
779 pts - 60-69yrs 
Hospital : 
8.2% 
All patients 73 40 
Noyez, Eck van 
(present study) 
1987-1992 
541 pts - 63.7 yrs 
Hospital : 
6.7% 
6-months : 
13.9% 
All patients 
 
6 months survivors 
 
76 
 
86 
60 
 
68 
Weintraub [I]: total study, Weintraub [II]: only patients between 60-69 years old (reference 14) 
 
It must be clear, however, that several points make the comparison difficult. First the studied 
patients population are operated in different time frames. This is not only important because 
of different surgical techniques, patient profile, but also because the indication for RECABG 
changed over the years.[11,12,18-22] In the early seventies, the majority of RECABG’s were 
performed because of progression of atherosclerosis in the native coronary system or due to 
incomplete revascularization. Later in the eighties, the reason for RECABG had shifted to 
predominantly fa ilure of the graft. In recent years, more and more patients are reoperated 
because of progression of the disease in the native system, in combination with patent arterial 
grafts.[22] Second, the age of the studied populations is different; varying between 56 and 80 
years, or even older.[16] Age is indicated in several studies as an important variable 
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influencing survival. [1,10-12,14,17] Third, in several studies the hospital period, mortality, is 
included or not included in the survival analysis. Fourth, it is difficult to compare the risk of 
the studied patient populations. Risk analysis models as Parsonnet- ,[23] or Euroscore are not 
use,[24] and the reported operative-, hospital- or 30-day mortality, probably an indication of 
the risk of the operated population, varies in all these studies.     
The two studies, most comparable with ours, are from Weintraub et al [14], especially in the 
section separately evaluating a group of patients aged between 60-69 yrs old, operated 
between 1975 and 1993( indicated as Weintraub [II] in Table 5). The difference is that this 
study began in 1975, of the 2030 described patients 471 patients were operated before 1985, 
but hospital mortality and long-term survival are comparable with our results for the entire 
group. The second study is from Shapira,[17] the reported 30-days mortality (3%) and long 
term survival ( 90%,74%) seems superior to our results. The number of patients and mean age 
of the studied population are comparable, however, the study starts in 1978 and ends in 1989. 
Looking to the indications for reoperation, this study shows a high percentage of incomplete 
revascularization (11.1%), a low percentage of combined graft failure and progression of the 
disease (22.5%). If we compare this with our previous study and other studies, it is clear that 
this patient population, is not comparable with our described population or other recent 
studies of patients undergoing RECABG.[10,13,14,15,16,22]    
 Starting our survival analysis at six months postoperatively, cardiac related survival 
seems only be influenced by age (older or younger than 65 years). Age is identified in several 
other survival studies, [1,10,11,12,14,17] however in contrast with a majority of these studies, 
co-morbidity factors and cardiac related variables are not identified as variables with a 
significant adverse effect on cardiac related longevity. However, diabetes (P=0.06), female 
gender (P= 0.07), and impaired left ventricular function (P=0.07), bend to significance in our 
analysis. After uni- and multivariate analysis impaired left ventricular function is identified as 
the only independent predictor of late cardiac related mortality after redo surgery. Impaired 
left ventricular function is identified by several other studies as a predictor for cardiac related 
mortality, however, other variables as diabetes, hypertension, emergency surgery and others 
identified in these reports were not significant in our analysis.[1,2,10-17]  
One criticism is that course that some variables are not included in our analysis. The most 
important is certainly completeness of the revascularization at the moment of the RECABG. 
In four patients (0.8%) it was preoperatively decided to do an incomplete revascularization 
(two patients with a single graft to the LAD and one patient with a single graft to the right 
coronary artery, and this despites pathology in the circumflex arteries, in another patient with 
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extensive pathology, only an additional IMA graft was constructed to a diseased vein graft to 
the LAD) All the other RECABG’s were performed with as starting point a complete 
revascularization. However, diffuse pathology, lack of graft material, make definition of 
completeness of revascularization in RECABG extremely difficult. The question is; is 
revascularization complete  if the surgeon performed all preoperatively planed grafts and 
distal anastomoses, or if the surgeon performed as much as possible of the preoperatively 
planned grafts and distal anastomoses, without increasing the risk for complications during 
the operation. It was even surprising that in our review of the literature, [1,11-17] only in the 
study of BW Lytle et al. is completeness of revascularization is analyzed.[11].  Completeness 
of revascularization is, however, not clearly defined and the study describes patients 
undergoing a RECABG between 1967-1984. As already mentioned in this discussion, it is 
difficult to compare these patients with our patients. Most of these patients had even not a 
complete revascularization at the CABG, and even during the RECABG completeness of 
revascularization varies between 51% and 75%. It is remarkable that a following study of the 
Cleveland Clinic, [12] completeness of revascularization is not analyzed. The changing 
profile of patients undergoing a RECABG, an increase of patients with progression of 
atherosclerosis in the native coronary arteries and patent arterial grafts, [22] only complicates 
the definition of complete revascularization. A patient with a patent IMA graft to the LAD, 
reoperated with new grafts to the distal right coronary artery and to the circumflex . But 
without a graft to a calcified diagonal branch, because of the risk of peroperative problems. Is 
this a complete revascularization or not? On the other hand, we realize, that in these patients it 
would be interesting to know if completeness of revascularization is important.  A recent 
study of Czerny et al showed indirectly that completeness of the revascularization affects 
significant recurrence of angina but could not show a difference in long term survival (mean 
follow-up 50 ± 23 months).[25]  
Another point of criticism is that secondary prevention and certainly medical therapy changed 
over the years. At our department, patients reoperated before 1992 received mostly no 
platelet- inhibiting agents, after the CABG. Systematic control of cholesterol or lipoprotein 
status, use of statins, are important but changed over the years. However, this information is 
not registered in our database and thus not available.    
 Inspite of the limitations of our study, the importance is that once patients survive the 
early postoperative period (six months) after RECABG, their cardiac related survival is 
influenced by age, and that an impaired left ventricular function is the only independent 
predictor for cardiac related mortality. These findings confirm the importance of the early 
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postoperative period and the identified variables, it seems that the early postoperative period 
is an executioner, selecting the strongest patients.  
 
 In conclusion, the long term survival in patients undergoing reoperative coronary 
artery surgery are acceptable. Once patients survive the first six postoperative months, only 
advanced age (> 65 years) is affecting long term cardiac survival and impaired left ventricular 
function is the only independent predictor of late cardiac mortality.    
 
References 
 
1. Salomon NW, Page US, Bigelow JC, Krause AH, Okies JE, Metzdorff MT Reoperative 
coronary surgery. Comparative analysis of 6591 patients undergoing primary bypass and 
508 patients undergoing reoperative coronary bypass. J Thorac Cardiovasc Surg 1990 ; 
100 : 250-260. 
2. Schmuziger M, Christenson JT, Maurice J, Mosiman E, Simonet F, Velebit V. 
Myocardial revascularization for the second time. Analysis of 458 reoperations and 2645 
single operations. Cardiovasc Surg 1994 ; 2 : 623-629. 
3. Noyez L, Skotnicki SH, Kaan GL, Hensen AG, de Jong Pl, Lacquet LK. Primaire 
myocardrevascularisaties versus heroperaties. Een evaluatie van perioperatieve 
morbiditeit en mortaliteit. Cardiologie 1996 ; 3 : 18-21. 
4. Sergeant P, Balckstone E, Meyns B, Stockman B, Jashari R.  First cardiological or 
cardiosurgical reintervention for ischemic heart disease after primary coronary artery 
bypass grafting. Eur J Cardiothoracic Surg 1998 ; 14 : 480-487. 
5. Blackstone EH Outcome analysis using hazard functional methodology. Ann Thorac Surg 
1996 ; 61(2 suppl) : S2-7. 
6. Eck van FM, Noyez L, Verheugt FWA, Brouwer RMHJ. Analysis of mortality within the 
six months after coronary reoperation. Ann Thorac Surg 2002 ; 74 : 2106-2112. 
7. Eck van FM, Noyez L, Verheugt FWA, Brouwer RMHJ.  Preoperative prediction of early 
mortality in redocoronary artery surgery. Eur J Cardiothoracic Surg 2002 ; 21 : 1031-
1036. 
8. Sergeant P, Blackstone E, Meyns B. Validation and interdependence with patient-
variables of the influence of procedural variables on early and late survival after CABG. 
KU Leuven Coronary Surgery Program. Eur J Cardiothorac Surg 1997 ; 12 : 1-19. 
  
104  
 
9. Loop FD, Lytle BW, Gill CC, Golding LAR, Cosgrove DM, Taylor PC. Trends in 
selection and results of coronary artery reoperations. Ann Thorac Surg 1983 ; 36 : 380-
388. 
10. Akins CW, Buckley MJ, Dagget WM, Hilgenberg AD, Vlahakes GJ, Torchiana DF, 
Austen WG. Reoperative coronary grafting: changing patient profiles, operative 
indications, techniques, and results. Ann Thorac Surg 1994 ; 58 : 359-365. 
11. Lytle BW, Loop FD, Cosgrove DM, Taylor PC, Goormastic M, Peper W, Gill CC, 
Golding LAR. Fifteen hundred coronary reoperations. J Thorac Cardiovasc Surg 1987 ; 93 
: 847-859. 
12. Loop FD, Lytle BW, Cosgrove DM, Woods EL, Stewart RW, Golding LAR, Goormastic 
M, Taylor PC. Reoperation for coronary atherosclerosis. Changing practice in 2059 
consecutive patients. Ann Surg 1990 ; 212 : 378-386. 
13. Christenson JT, Schmuzinger M, Simonet F. Reoperative coronary artery bypass 
procedures: risk factors for early mortality and late survival. Eur J Cardiothoracic Surg 
1997 ; 11 : 129-133. 
14. Weintraub WS, Jones EL, Craver JM, Grosswald R, Guyton RA. In-hospital and long-
term outcome after reoperative coronary artery bypass surgery. Circulation 1995 ; 
92[suppl II] : II-5—II-57. 
15. Yamamuro M, Lytle BW, Sapp SK, Cosgrove DM, Loop FD, McCarthy PM. Risk factors 
and outcomes after coronary reoperation in 739 elderly patients. Ann Thorac Surg 2000 ; 
69 : 464-474. 
16. Blanche C, Kahn SS, Chaux A, Denton TA, Sandu M, Tsai T-P, Trento A. Cardiac 
reoperations in octogenarians: Analysis of outcomes. Ann Thorac Surg 1999 ; 67 : 93-98. 
17. Shapira I, Isakov A, Heller I, Topilsky M, Pines A. Long-term follow-up after coronary 
artery bypass grafting reoperation. Chest 1999 ; 115 : 1593-1597. 
18. Abramov D, Tamariz MG, Fremes SE, Guru V, Borger MA, Christakis GT, Bhatnagar G, 
Sever JY, Goldman BS.Trends in coronary artery bypass surgery results: a recent,9-year 
study. Ann Thorac Surg 2000 ; 70 : 84-90. 
19. Noyez L, Lacquet LK. Cardiac reoperations with a patent internal mammary artery graft. 
A double challenge? Cardiovascular Surgery 1995; 36 : 13-15. 
20. Borger MA, Rao V, Weisel RD, Floh AA, Cohen G, Feindel CM, Scully HE, 
Mickleborough LL, Yau TM. Reoperative coronary bypass surgery: effect of patent grafts 
and retrograde cardioplegia. J Thorac Cardiovasc Surg 2001 ; 121 : 83-90. 
  
105  
 
21. Brener SJ, Loop FD, Lytle BW,Ellis SG, Cosgrove DM, Topol EJ. A profile of candidates 
for repeat myocardial revascularization: implications for selection of treatment. J Thorac 
Cardiovasc Surg 1997 ; 114 : 153-161. 
22. Eck van FM, Noyez L, Verheugt FWA, Brouwer RMHJ. Changing profile of patients 
undergoing redo-coronary artery surgery. Eur J Cardiothoracic Surg 2002 ; 21 : 205-211. 
23. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for 
evaluating the results of surgery in acquired adult heart disease. Circulation  1989 ; 
79(suppl I) : I-3-I-12. 
24. Nashef SAM, Roques F, Michel P Gauducheau E, Lemeshow S, Salamon R. European 
system for cardiac opertive risk evaluation (EUROscore). Eur J Cardio-thorac Surg 1999 ; 
16 , 9-13. 
25. Czerny M, Zimpfer D, Kilo J, Gottardi R, Dunkler D, Wolner E, Grimm M. Coronary 
reoperations: recurrence of angina and clinical outcome with and without 
cardiopulmonary bypass. Ann Thorac Surg 2003 ; 75 : 847-852. 
  
106  
 
  
107  
 
 
 
 
CHAPTER VIII 
 
 
EVALUATION OF LONG TERM QUALITY OF LIFE AFTER REOPERATIVE 
CORONARY ARTERY SURGERY. PRELIMINARY RESULTS. 
 
 
Luc Noyez, Astrid Schultz, Stefan M. van der Heide, 
 Frans M. van Eck, René M.H.J. Brouwer 
 
Netherlands Heart Journal 2003; 11: 500-505.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
108  
 
Abstract 
 
Objective: The risks of reoperative coronary artery bypass surgery (RECABG) still exceed 
those of a primary revascularization and late results are not so favourable either. The subject 
of the present study is an evaluation of the long term quality of life after RECABG.  
Methods: We studied the outcome of 541 patients who underwent a RECABG from January 
1987 to December 1998.  The endpoint of the study was December 2002, or patients death.  
Quality of life, using the EuroQol registration was evaluated.   
Results:  Hospital mortality was 6.7%. Follow-up was 95.6% complete, mean 7.7 years. 
There were 177 late deaths. The cumulative survival rates were 83.8%, 76.9%, and 60.6%, 
cardiac survival rates: were 84.8%, 78.5%, and 66.5%, at the 1-year, 5-years, and 10-year 
follow-ups, respectively. For 255 patients (89%) NYHA and EuroQol information was 
complete. In total 23% of the patients were in NYHA class I, 51% in class II, 21% in class III 
and 5% were in class IV. In the EuroQol registration 54% of the patients declared they have 
no mobility problems, 85% no problems with self-care, and 65% no problems with usual 
activities. However, 60%, suffered from moderate pain, or discomfort, and 33% from anxiety 
or depression. On the visual analogue scale (mean 63.5), 13% of the patients scored > 90, 
68% between 50 and 90 and 19 % of the patients < 50.  
Conclusion: The long-term results of cumulative survival and cardiac survival,NYHA class 
in our patient population who underwent RECABG are comparable with other studies. 
Quality of life is acceptable regarding to the high risk of a RECABG.  
 
 
Key words: 
Myocardial revascularization, reoperation, follow-up, quality of life, EuroQol 
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1. Introduction. 
 
The risks of reoperative coronary artery bypass surgery (RECABG) still exceed those 
of a primary revascularization. Several reports discuss late survival and related variables ando 
late results are not very favourable either. However, little or nothing has been reported 
concerning long term quality of life after RECABG, an important issue in a ‘high risk’ patient 
population.1-8 
The intention of this study is to evaluate long-term quality of life of patients 
undergoing a RECABG, using the EuroQol registration,9 and also the feasibility of this 
EuroQol survey in our data registration. 
 
2. Patients and methods. 
2.1 Patients 
With the aid of our database, Coronary Surgery Database Radboud Hospital 
(CORRAD), we identified a series of 541 patients undergoing a first RECABG from January 
1987 to December 1998 at the UMC St. Radboud Nijmegen. Hospital mortality was 36/541 
(6.7%) and the 505 surviving patients were entered into our follow-up.10    
 
2.2 Follow-up. 
 Follow-up information is based on data from cardiologists, family doctors and an 
annual survey sent directly to the patients. A cross sectional follow-up was performed in 
December 2002. If there was no response from the patient, the information was traced by 
telephone contact with the patient, family, doctor, or government  records. When death had 
occurred, the cardiologists, family doctor, or patients family was contacted to identify the 
cause of death. During the cross sectional follow-up patients were asked to inform us about 
their functional, New York Heart Association, classification and quality of life by using the 
EuroQol registration.9 The EuroQol-method is a standardised, generic (not disease specific) 
method for describing and evaluating health-related quality of life. It collects data about 
physical, mental and social functioning. The questionnaire (Table 1) consists of questions 
about mobility, self-care, normal day activities, anxiety and depression, pain and discomfort  
and a Visual Analogue Scale (VAS), a gauge by which the patient can express his current 
state of health on a scale of 0 (worst imaginable health state) to 100 (best imaginable health 
state) The relation between quality of life and several pre- and perioperative variables was 
studied (Appendix 1)  
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Table 1. Results of the EuroQol registration at follow-up. 
 EuroQol Registration     Number of patients (n=255) % 
Mobility  
 I have no problems in walking about    139   54.5 
 I have some problems in walking about    104   40.8 
 I  can not walk alone – I am confined to bed   14   5.5 
Self-care  
 I have no problems with self-care    217   85.1 
 I have some problems washing or dressing myself   30   11.8 
 I am unable to wash or dress myself    8   3.1 
Usual  activities (work, study, housework, family, leisure activities) 
 I have no problems with performing my usual activities  165   64.7 
 I have some problems with performing my usual activities 80   31.4 
 I am unable to perform my usual activities   10   3.9 
Pain/discomfort 
 I have no pain or discomfort     69   27.1 
 I have moderate pain or discomfort    154   60.4 
 I have extreme pain or discomfort    49   19.2 
Anxiety / Depression 
 I am not anxious or depressed     162   63.5 
 I am moderately anxious or depressed    83   32.5 
 I am extremely anxious or depressed    10   3.9 
 
 
2.3 Statistical analysis. 
 Data were presented as frequency distribution and simple percentages, the VAS as 
mean ± standard deviation. Survival was calculated using Kaplan-Meier method. To test 
which patient variables were associated with the different domains of the EuroQol–
registration, univariant analysis, was used. A p-value of 0.05 or less was considered 
significant.  
  
3. Results. 
 
 A total of 505 patients with a mean age 63.6±8.5, mean 64.1, range 32-91 years were 
included in the follow-up, mean follow-up was 7.7 ± 3.8 years. Follow-up was 96% complete, 
20 patients were lost for follow-up.  The cumulative survival rates for the total patient 
population (541 patients) were 83.8%, 76.9%60.6% at the one-year, five-year, and ten-year 
follow-up respectively. Cardiac event- free survival rates were 84.8%, 78.5% and 66.5% 
respectively. (figure 1) 
 At the moment of the cross-sectional follow-up, December 2002, 287 patients were 
registered as alive. Of 255 patients (89%), NYHA and EuroQol information was complete.  
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Figure 1. Cardiac event-free survival of the total patient population. 
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The results of the pre and post NYHA registration of this patient population are presented in 
figure 2.   
 
Figure 2. New York Heart Association functional class of 255 patients preoperatively (Pre -op) 
and at follow-up. 
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The results of the EuroQol registration are summarized in table 1. Interesting is that 
despite the fact that most patients have no problems with mobility (54%), self-care (85%), 
usual activities (65%), and anxiety or depression (63%), about 60% declare that they are 
suffering form moderate pain and discomfort. Univariate analysis identified several variables 
related to this EuroQol registration (table 2). Women, have a significant lesser quality of life 
regarding to mobility (p=0.031), normal activities (p=0.011), pain, discomfort (p=<10-4), and 
anxiety and depression (p=0.02). Diabetics (p=0.004), patients with peripheral vascular 
 1-year 5-years 10-years 
Survival (%) 84.8 78.5 66.5 
Patients at risk 446 333 141 
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pathology (p=0.019) and a between myocardial infarction (p=010) have significant more 
problems with mobility. Hypertensive patients (p=0.033) and patients with a history 
neurological disease (p=0.03) have a significant lesser mobility postoperative. Patients with a 
history of a renal disease have more problems with normal activities (p= 0.008).  
 
Table 3.  Studied variables tested for their aossciation with the EuroQol registration (univariate 
analysis) -significant p-values are marked bold 
Variable  Mobility Self-care  Usual 
activities 
Pain 
discomfort 
Anxiety 
Depression 
Age 0.61 0.31 0.14 0.64 0.31 
Sex 0.031 0.54 0.011 <104 0.02 
Diabetes  0.004 0.08 0.40 0.11 0.07 
Hypertension 0.23 0.033 0.29 0.14 0.27 
Hyperlipidemia  0.71 0.39 0.99 0.82 0.36 
Vascular disease 0.019 0.70 0.29 0.63 0.47 
Neurological disease 0.47 0.033 0.61 0.84 0.46 
Renal disease 0.062 0.056 0.008 0.41 0.72 
Lung disease  0.74 0.47 0.41 0.39 0.88 
PTCA  0.96 0.27 0.76 0.62 0.43 
Preoperative MI 0.18 0.88 0.73 0.10 0.75 
Between-MI 0.010 0.19 0.26 0.12 0.94 
Sinus rhythm  0.68 0.17 0.38 0.24 0.73 
IMA-graft 0.17 0.39 0.76 0.33 0.38 
Impaired left ventricular function 0.12 0.91 0.68 0.42 0.31 
Operative status 0.47 0.19 0.26 0.39 0.16 
Mild valve disease 0.99 0.13 0.89 0.89 0.74 
Myocardial protection 0.98 0.72 0.54 0.52 0.68 
Perioperative MI 0.54 0.32 0.95 0.88 0.64 
 
The Visual Analogue Score had a mean of 63.5± 20.5 (median 65 , range 10-100). Thirty-two 
patients (12.5%) had a VAS > 90, 49 patients (19.2%) a VAS of < 50, 174 patients (68.2%) 
indicated a score between 50 and 90. Figure 3 presents the result as a histogram.        
 
4. Discussion.  
  
 Reoperative coronary artery surgery is still high-risk surgery. Despite advances in 
surgical techniques and myocardial protection, mortality and morbidity rates of RECABG still 
exceeds those of CABG. This concerns not only the perioperative results but also the long-
term results. Most studies deal with perioperative and long term survival results and only a 
few of these reports discuss quality of life, mostly by mean of the functional status.1-8,10 
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Figure 3. Results of the Visual Analogue Score. 
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 The ACC/AHA guidelines for CABG surgery suggest that improvement in quality of 
life is a primary indication for CABG surgery.11 The importance of quality of life was 
recognized and referred to as “not just the absence of death but life with the vibrant quality 
that we associate with the vigour of youth” by Elkington in 1966 .12 Quality of life constitutes 
a person’s perceptions of his personal physical and mental well-being, health, and symptoms 
rather than the surgeon’s view of technical success. It is generally accepted that patients with 
larger preoperative health status deficits were more likely to have an improvement in their 
quality of life, but also that these patients have a higher perioperative mortality and morbidity 
risk.  Therefore evaluation of quality of life in high-risk patients, such as patients undergoing 
a RECABG, is important and must seen as a complementary approach to the usual 
evaluations.  
 Our long term survival and cardiac–event free, were comparable with other reports 
and discussed in a previous study.1-8,10 Registration of functional NYHA class shows that 
even in long term, patients benefit of the RECABG.1-8 It is known that angina can affect 
quality of life, but it is also known that health status is much more than an evaluation of 
angina.13  
There is however no consensus on the best approach to asses quality of life, 
particularly after open heart surgery. In previous reports we evaluated quality of life using the 
Duke Activity Status index in young people,14 and the Barthel index in an elderly 
population.15 In literature , numerous questionnaires have been used, tested. However, none 
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has been accepted as the gold standard. In this study we use the EuroQol registation.9 This 
EuroQol registration addresses various aspects of quality of life, is standardised, widely 
accepted, but not disease specific,. The questions are simple and the questionnaire is easy to 
complete.      
  At our cross sectional follow-up we had a good response, 89% of the returned 
questionnaires were complete. It must be noted that some patients only completed the NYHA-
classification or only the EuroQol registration; these are not, however, incorporated in our 
study. Interpretation of our results is of course difficult, we have no other study for 
comparison. In our search of literature we did not find any specific studies concerning quality 
of life after RECABG, and after such a long follow-up period. Eighty-five percent of patients 
without problems with self-care is certainly a good result in this patient population. More 
difficult is the interpretation of the results of mobility and usual activities, anxiety or 
depression. Interesting however, is that about 60% of the patient suffer from moderate pain or 
discomfort.  This is an important results and it is imperative that this point is discussed 
preoperatively with patients undergoing a RECABG. The visual analogue scale, asking the 
patients how they evaluate their own health state, shows that most patients accept their life 
quality as good. More interesting in this EuroQol registration is, however, that we identified, 
female gender, diabetes, vascular pathology, hypertension, renal pathology, neurological 
pathology and a between myocardial infarction as preoperative variables related to the post 
operative quality of life. As said, comparison of these results is difficult because of the lack of 
similar studies. However, in a prospective study of quality of life before and after open heart 
operations using the Nottingham health profile,16 female gender was even identified as an 
independent predictor of less improvement of quality of life. The relation of several variables 
on the different domains of quality of life seems logical, namely diabetes, vascular pathology 
on mobility, neurological disease on self-care, renal disease on usual activity. On the other 
hand, it is surprising that left ventricular function and operative status are not related to the 
EuroQol registration. However, operative status (acute and emergency) was identified as an 
independent variables for early mortality, and impaired left ventricular function as an 
independent variable for late cardiac mortality. 8,10  So only a limited number of these patients 
were included in the cross sectional follow-up of December 2002. 
 We realize that our study has many shortcomings and is not complete. Most important 
is of course the lack of preoperative registration of quality of life. However, the aim of the 
study was to gain an idea of quality of live of patients undergoing a RECABG.  Because of 
the good response on the EuroQol registration questionnaire during this study, we now 
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include this questionnaire preoperatively in our CORRAD-data registration and also in our 
annual follow-up. Certainly in high-risk patients, as those undergoing RECABG, but also in 
other high risk populations, such as elderly, this “subjective“ information can augment 
clinical decision-making by helping to identify those who will have a quality of life benefit 
from the operation. For instance, in a female diabetic patient, with vascular comorbidity, 
presenting for a RECABG, and identified as a high risk patient, complaining in the first place 
of mobility-problems, we can be more restrictive because, female gender, diabetes and 
vascular pathology seems to be related to a lesser improvement of mobility postoperative.          
  
 In conclusion this study show acceptable long term results concerning quality of life at 
long term after RECABG. Further analysis of this subject, can be helpful in making the 
decision to operate or not. Important is also that the EuroQol registration for quality of life, 
seems us very practical and will be used as well preoperative as postoperative in our cardiac 
surgery data registration. 
 
*We thank Dr. Eric Roberston, anaesthesiologist, for his correction of the English text 
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Appendix 1. Definitions of studied variables 
 
Variable  Definition 
Age (years) age < 65, and age  ³ 65 years 
Sex Male, Female  
Diabetes Diet-controlled, oral therapy or insulin dependent diabetes 
Hypertension Systolic blood pressure > 160 mmHg, or diastolic pressure > 100 mmHg. Or antihypertensive medication.  
Hyperlipidemia  Total cholesterol > 250mg/dl or triglyceride level 200 mg/dl 
Vascular disease Peripheral -, abdominal vascular pathology or operation 
Neurological 
disease 
Cerebrovascular accidents and /or transient ischemic attack 
Renal disease Renal failure (creatinine ³ 150 mmol /L) preoperative dialysis, renal transplantation 
Lung disease Chronic obstructive pulmonary disease and/or history of previous lung disease 
PTCA History of previous percutaneous transluminal coronary angioplasty 
Pre-M.I. History of myocardial infarction before the first operation 
Between M.I. History of myocardial infarction between the first operation and the reoperation. 
Sinus rhythm Preoperative sinus rhythm 
IMA-graft Patent Internal Mammary Artery graft at the reoperation 
Impaired left 
ventricular 
function 
Ejection fraction <30% or indicated by the surgeon at the moment of the 
reoperation 
Operative status 
Elective: patients with stable cardiac function, usually scheduled at least one day 
prior to the surgical procedure. Urgent: surgery is required within 24 hours after 
admission, Emergency: operation for evolving infarction, ischemia not responding 
to medical therapy, or cardiogenic shock. 
Mild valve 
disease 
Combined valve disease, not requiring surgical intervention 
Myocardial 
protection 
Way of delivery the cardioplegic solution 
Perioperative  MI A new Q wave and a CPK-MB% ³ 10% 
PTCA : percutane transluminal coronary angioplasty, M.I. myocardial infarction, IMA : internal 
mammary artery. * Other technique, not incorporated in the analysis , because of the limited number 
op patients (5) . 
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CHAPTER IX 
 
 
SUMMARY AND CONCLUSIONS 
 
SAMENVATTING EN BESLUITEN 
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Chapter I  
After a review of the complexity of hazards related to reoperative coronary artery bypass 
grafting, the objectives of this thesis are outlined. 
· What is changing in the patient population undergoing reoperative myocardial 
revascularization especially regarding strategies in primary myocardial 
revascularization? 
· Which variables are responsible for the persistently elevated mortality of reoperative 
myocardial revascularization, and how can we inform patients and family about this 
risk? 
 
Chapter II 
In this chapter the changing profile of patients undergoing reoperative myocardial 
revascularization are studied. A series of 582 patients undergoing a first redo, between 
January 1987 and June 2000 at the University Medical Center Nijmegen, St. Radboud is 
described.  There is a shift to an increasing number of older patients, with more coexisting 
disease, and with more patent arterial grafts. The increasing number of patients reoperated for 
isolated progression of atherosclerosis in the native coronary arteries confirms the palliative 
aspect of bypass surgery.  
 
Chapter III 
 This chapter deals with the increasing number of patients undergoing a redo with a 
patent internal mammary artery graft. The good survival in patients when return of angina is 
the only symptom suggests a more restrictive approach. An analysis of short and long time 
results, clinical, functional and subjective status of 71 patients with a patent internal 
mammary artery graft undergoing RECABG is presented. Despite a perioperative mortality of 
7%, we conclude that the improved clinical, functional and subjective status of the patients 
justify this kind of surgery. 
 
Chapter IV 
 High mortality rates remains in RECABG. In Chapter IV we focus on mortality within 
the first six months – the so-called ‘early post-operative phase’ following reoperative 
myocardial revascularization. Mortality is assessed at three different points: hospital 
mortality, mortality at six months and outpatient perioperative mortality, as death occurring 
from the time of hospital discharge to six months postoperatively. This study emphasized that 
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early mortality is influenced by several variables at different times. Insight in this time-related 
influence of variables help point out factors contributes to hospital mortality and  death after 
hospital discharge.  
 
Chapter V 
 Chapter V is a result of the analysis in the previous chapter. Because the high risk for 
early mortality after reoperative myocardial revascularization we constructed a predictive 
model based on preoperative variables. The best predictive variables for early mortality are 
diabetes, vascular-, lung-disease, a myocardial infarction between the primary and the 
RECABG, acute- and emergency operation and the operative period. Evaluation of our 
predictive model shows a specificity of 97%, a sensitivity of 33% and a predictive value of a 
positive test 63% and 90% for a negative test. This study shows that patients can be stratified 
according to their early mortality risk.  Information that can be used to inform patients, and to 
discuss the opportunity of RECABG.  
 
Chapter VI 
 Because it is not only important to discuss preoperatively the risk, but also to identify  
high risk patients for early postoperative mortality, the analysis performed in chapter V is 
repeated for the patients surviving the operation and includes also peroperative variables. 
Diabetes, lung disease, emergency operation and a perioperative myocardial infarction are the 
best predictive variables. The predictive value of a positive test is 79% and 95% for a 
negative test. With this model we can inform not only patients but also family, family doctors 
and cardiologists about the risk for early mortality, after hospital discharge.    
 
Chapter VII 
 In this chapter, we analyzed long term cardiac survival of the 466 patients who 
survived the first six months after a RECABG.  Mean follow-up was 7.7 ± 3.8 years (1-17 
years), and follow-up was 95.6% complete. One year cardiac survival was 98.2%, 5-year: 
91.0%, 10-year: 78.7% and 14-year survival 60.2%. Cardiac survival was only significantly 
better for patients aged 65 years or less at the time of RECABG. Impaired left ventricular 
function was identified as the only independent predictor of late cardiac-related mortality. 
This chapter confirms again the importance of the first six postoperative months after 
RECABG. 
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Chapter VIII 
 This chapter concerns quality of life after RECABG. Although improvement of quality 
of life is accepted as a primary indication for myocardial revascularization, little or nothing is 
reported concerning quality of life after RECABG in literature. Our results of quality of life 
analysis after reoperative coronary artery surgery using the EuroQol score are presented. 
Despite all the limitations of this study, we conclude that patients have an improved 
functional status and quality of life. On the other hand, the EuroQol registration seems a very 
useful system and is now integrated pre- and postoperatively in our CORRAD ( Coronary 
Surgery Database Radboud) registry.    
 
 
* Dr. Eric N. Robertson, Anesthesiologist, is thanked for his correction of the English text. 
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Hoofdstuk I 
Na een overzicht van de complexe problematiek bij coronaire heroperaties, worden de 
hoofdlijnen van dit proefschrift  naar voor gebracht. 
· In welke mate is de populatie van patiënten, die een heroperatie ondergaan 
veranderd en dit in relatie tot de veranderde strategieën bij de primaire 
ingrepen? 
· Welke factoren spelen een rol in de hoge mortaliteit bij heringrepen en kunnen 
we deze mortaliteit inschatten? Op deze manier kunnen we tot een betere 
selectie van goede operatiekandidaten komen maar ook betere informatie 
verschaffen aan patiënt en familie. 
 
Hoofdstuk II 
In dit hoofdstuk wordt het profiel van patiënten die een coronaire heringreep 
ondergaan bestudeerd. En groep van 582 patiënten, die een heringreep ondergingen tussen 
januari 1987 en juni 2000  in het Universitair Medisch Centrum Nijmegen, St. Radboud wordt 
beschreven. Steeds meer en meer ouderen, risico-patiënten, en patiënten met een goed 
functionerende arteriële graft ondergaan een heroperatie. Tevens blijkt er een stijgend aantal 
patiënten te zijn met recidief klachten ten gevolge van het verder aantasten van de eigen 
coronair arteriën. 
 
Hoofdstuk III 
 Dit hoofdstuk analyseert de resultaten van patiënten met een goed functionerende 
arteriële graft die een heroperatie ondergaan. In deze studie zijn 71 patiënten betrokken. De 
perioperatieve mortaliteit bedraagt 7%, maar de  goede klinische, functionele en subjectieve 
resultaten, zowel op korte als op langere termijn verantwoorden de heringreep bij deze 
populatie.  
 
Hoofdstuk IV 
 De hoge mortaliteit bij heringrepen is een blijvend punt van discussie en 
onderzoeksthema. In dit hoofdstuk wordt de vroegtijdige mortaliteit – binnen de eerste zes 
maanden na de operatie geanalyseerd. Specifiek in deze analyse is dat de mortaliteit wordt 
geanalyseerd op drie momenten. Ten eerste: de mortaliteit zes maanden na de ingreep, ten 
tweede: de ziekenhuis mortaliteit, zijnde de peroperatieve en  alle mortaliteit tijdens het 
postoperatieve ziekenhuisverblijf en ten derde: de vroegtijdige ‘out-of-hospital ‘mortaliteit, 
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dwz  alle mortaliteit die optrad na het ziekenhuisontslag maar binnen de eerst zes maanden 
postoperatief. Onze analyse toont aan dat verschillende factoren op verschillende tijdstippen 
en met een verschillend belang de vroegtijdige mortaliteit beïnvloeden.  
 
Hoofdstuk V 
 Dit hoofdstuk is een resultaat van de analyse verricht in hoofdstuk IV. Op basis van 
deze gegevens wordt in hoofdstuk V een model gepresenteerd voor het preoperatief inschatten 
van de vroegtijdige mortaliteit. Diabetes, vasculaire-, long-problematiek, een hartinfarct 
tussen de primaire operatie en de heringreep, acute en spoedingrepen, alsmede de operatieve 
periode, zijn variabelen die onafhankelijk bijdragen tot de vroegtijdige mortaliteit na 
heringrepen. Het ontworpen model heeft een specificiteit van 97%, sensitiviteit van 33%, de 
voorspelende waarde van een positief resultaat is 63% en 90% bij een negatieve test.  Deze 
informatie kan gebruikt worden om patiënten, familie, huisartsen en  cardiologen preoperatief 
te informeren omtrent het risico van hun heringreep. 
 
Hoofdstuk VI 
 In dit hoofdstuk wordt de analyse van het vorige hoofdstuk hernomen, maar met  het 
verschil dat nu enkel patiënten die de heroperatie overleefden, en een aantal operatieve 
variabelen in de analyse zijn betrokken.  Het belang is tweeërlei: ten eerste is het niet alleen 
belangrijk om patiënten en familie preoperatief te informeren over het mortaliteit risico, maar 
ook om na de operatie opnieuw hun kansen te bespreken. Ten tweede, zeker voor 
behandelende cardiologen, kan men op deze manier patiënten met een verhoogde kans op een 
out-of-hospital mortaliteit identificeren en eventueel specifiek gaan behandelen.  
Diabetes, longproblematiek, een spoedingreep en het optreden van een perioperatief 
myocardinfarct zijn  factoren die onafhankelijk bijdragen tot een verhoogde kans op 
vroegtijdige out-of-hospital mortaliteit. Opnieuw, in analogie met hoofdstuk V, werd een 
voorspellend model gemaakt. De voorspellende waarde van een positieve test bedraagt 79% 
en 95% voor een  negatieve test. In de marge van deze analyse bleek dat het gebruik van 
retrograde toediening van de cardioplegische vloeistof een significante rol speelt bij het 
beperken van een perioperatief myocardinfarct.      
 
Hoofdstuk VII 
 De lange termijn cardiale overleving van de 466 patiënten, die de eerste zes 
postoperatieve maanden overleefden wordt beschreven. De gemiddelde follow-up bedroeg 7.7 
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± 3.8 jaren (1-17 jaar), en de follow-up was voor 95.6% volledig. De 1-jaars cardiale 
overleving was 98.2%, 5-jaars: 91.0%, 10-jaars: 78.7% en de 14-jaars overleving  60.2%. 
Deze overleving wordt significant beïnvloed door de leeftijd op het ogenblik van de 
RECABG ( 65jaar) en een verminderde linker ventrikel functie is de enige onafhankelijke 
predictor voor cardiale dood. Dit hoofdstuk geeft nogmaals aan hoe belangrijk de eerste zes 
postoperatieve maanden na RECABG zijn. 
 
Hoofdstuk VIII 
 In dit hoofdstuk ligt de nadruk op de kwaliteit van leven. Het verbeteren van de 
levenskwaliteit is een primaire behandelingsindicatie bij mensen met ischemische 
hartklachten. Des ondanks is er in de literatuur weinig of niets beschreven over de kwaliteit 
van leven na coronaire heroperaties. Onze resultaten, waarbij kwaliteit van leven werd 
geregistreerd door middel van de EuroQol registratie worden gepresenteerd. Het is een studie 
met heel wat beperkingen maar toch besluiten we dat deze patienten zowel op functioneel 
gebied als in kwaliteit van leven het goed stellen. Daarnaast lijkt de EuroQol registratie een 
goed hanteerbare en betrouwbare methode om de kwaliteit van leven te evalueren. In de 
huidige CORRAD-registratie ( Coronary Surgery Database Radboud) wordt deze EuroQol  
zowel preoperatief als postoperatief geregistreerd.  
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